

Curriculum Vitae

Jan H.M. Schellens

PERSONAL HISTORY

Date of birth

November 13, 1956

Nationality

Dutch

Work address

The Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands
Phone (work) 31 (0)20-512 2446 (secretary)
31 (0)20-512 9111 (general)
Fax 31 (0)20-512 2572
E-mail j.schellens@nki.nl

Brief biosketch:

Jan HM Schellens, MD PhD studied chemistry and medicine. He is board certified Medical Oncologist and Clinical Pharmacologist. He is head of the Department of Clinical Pharmacology of the Division of Medical Oncology of the Netherlands Cancer Institute, Amsterdam NL. He is full professor of Clinical Pharmacology, Utrecht University, Department of Pharmaceutical Sciences, Utrecht, NL. Main research interests are:

- early clinical trials and translational research, focused on targeted therapy
- development and validation of biomarkers for clinical research: CTCs, ctDNA, CECs
- pharmacogenotyping, focus on DPYD
- oral development of taxanes

Recent update of peer reviewed publications:

- >750 peer reviewed publications
- H-index 80 (Google Scholar and 70 web of science)
- >30,000 citations (>21,000 web of science)

Ongoing clinical trials:

PI or local PI of 63 early clinical and pharmacological trials

Teaching and training:

Head of the largest training facility for Clinical Pharmacology in the Netherlands
Teaching of undergraduate and graduate students Dept. Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, NL

Education and qualifications

Leadership Training course	Teaching institute "De Baak", 3 weeks course
"Visitatie" training	NIV (Dutch Internists Society), 3 March 2014
Good Clinical Practice/WMO	NKI-AVL, Amsterdam, The Netherlands, 20 November 2013, certified by Dutch Society for Medical Oncology (one full day training), formal Dutch examination: certification obtained

Good Clinical Practice	NKI-AVL, Amsterdam, The Netherlands, 12 December 2012, certified by Dutch Society for Medical Oncology (one full day training)
Good Clinical Practice	Quintiles, Amsterdam, The Netherlands, 21 December 2011 (one full day training)
START module Communication	Teach the teacher, Amsterdam, 15 December 2011 (one full day training)
Good Clinical Practice	Quintiles, Amsterdam, The Netherlands, 14 December 2010 (one full day training)
Good Clinical Practice	Quintiles, Amsterdam, The Netherlands, 21 May 2010 (one full day training)
Good Clinical Practice	NKI-AVL, The Netherlands, 06 October 2004 (one full day training)
Basic Life Support	NKI-AVL, The Netherlands, 11 November 2010
Board certified Clinical Pharmacologist	1997
Board certified Pharmacologist	1994
Advanced Clinical Drug Research Lecture Series)	University of Leiden, The Netherlands, 1994 (1 week) (Boerhaave (principle lecturer: Dr. C.C. Peck, Boerhaave Professor)
Board certified Medical Oncologist	1993
Netherlands Board of Internal Medicine	1991
PhD	Leiden University (supervisor Prof. Dr. D.D. Breimer), 1988
BIG registration	69023712201
Basic Workshop in Pharmacokinetics	Department of Pharmacy University of Manchester, United Kingdom, 1984 (1 week) [head: Prof. M. Rowland]
Doctoral exam	Utrecht University, The Netherlands, 1983 (cum laude)
B.Sc. (chemistry)	Utrecht University, The Netherlands, 1978
Course Pascal	Utrecht University, The Netherlands, 1978
Course Fortran	Utrecht University, The Netherlands, 1978

Employment history

2007 - present	Head division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, NL
1999 - present	Professor of Clinical Pharmacology, Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, NL
1996 - present	Staff Member Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, NL
1991 - 1996	Head of the Laboratory of Experimental Chemotherapy and Pharmacology, and Staff Member Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, NL

Publications (1987 - present)

Papers

- 1 **Schellens JHM**, Breimer DD. Variability in drug oxidation: importance of genetic constitution. *Pharmaceut Weekbl [Sci]* 1987; 9: 85-90
- 2 **Schellens JHM**, Soons PA, Breimer DD. Lack of bimodality in nifedipine kinetics in a large population of healthy subjects. *Biochem Pharmacol* 1988; 37: 2507-10
- 3 **Schellens JHM**, Van der Wart JHF, Danhof M, Van der Velde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in man as assessed by a 'cocktail' approach. *Br J Clin Pharmacol* 1988; 26: 373-84
- 4 **Schellens JHM**, Van der Wart JHF, Hoevers JW, Breimer DD. Gas chromatographic determination of sparteine and 2- and 5-dehydrosparteine in plasma and urine. *J Chromatogr Biomed Appl* 1988; 431: 203-09
- 5 Breimer DD, **Schellens JHM**, Soons PA. Nifedipine: variability in its kinetics and metabolism in man. *Pharmac Ther* 1989; 44: 445-54
- 6 **Schellens JHM**, Van der Wart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine and mephenytoin in man, as assessed by a 'cocktail' study design. *J Pharmacol Exp Ther* 1989; 249: 638-45
- 7 **Schellens JHM**, Janssens AR, Van der Wart JHF, Van der Velde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach. *Eur J Clin Invest* 1989; 19: 472-79
- 8 Breimer DD, **Schellens JHM**. A "cocktail-strategy" to assess in vivo oxidative drug metabolism in man. *TIPS* 1990; 11: 223-25
- 9 **Schellens JHM**, Van der Wart JHF, Breimer DD. Correlation between mephenytoin polymorphism and phenytoin, methylphenytoin and phenobarbital hydroxylation as assessed in a panel of healthy subjects. *Br J Clin Pharmacol* 1990; 29: 665-71
- 10 **Schellens JHM**, Soons PA, Van der Wart JHF, Hoevers JW, Breimer DD. Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. *Br J Clin Pharmacol* 1991; 31: 175-78
- 11 **Schellens JHM**, Van Haelst IMM, Houston JB, Breimer DD. Nonlinear first-pass metabolism of nifedipine in healthy subjects. *Xenobiotica* 1991; 21: 547-55
- 12 **Schellens JHM**, Ghabrial H, Van der Wart JHF, Bakker EN, Wilkinson GR, Breimer DD. Differential effect of quinidine on the disposition of nifedipine, sparteine and mephenytoin in man, as assessed by a 'cocktail' study design. *Clin Pharmacol Ther* 1991; 50: 520-28
- 13 Soons PA, **Schellens JHM**, Roosemalen MCM, Breimer DD. Analysis of nifedipine and its pyridine metabolite dehydronifedipine in blood and plasma: review and improved HPLC methodology. *J Pharm Biomed Anal* 1991; 9: 475-84
- 14 Gielen M, El Khoufi A, De Vos D, Kolker HJ, **Schellens JHM**, Willem R. Bis[di-n-butyl(tri- and tetrafluorobenzoato)]tin oxides: synthesis, characterization and in vitro antitumour activity. *Bull Soc Chim Belg* 1993; 102: 761-64
- 15 **Schellens JHM**. Variability in elimination and response of drugs. *J Drug Therapy Research* 1993; 18: 237-41
- 16 **Schellens JHM**, Loos W, Beijnen JH, Stoter G, Verweij J. Sensitive isocratic HPLC determination of EO9, a novel indoloquinone cytotoxic drug, in plasma and urine. *J Chromatogr Biomed Appl* 1993; 615: 309-15
- 17 Ma J, Verweij J, Kolker HJ, Van Ingen HE, Stoter G, **Schellens JHM**. Pharmacokinetic-dynamic relationship of cisplatin *in vitro*. Simulation of an iv bolus, 3 hr and 20 hr infusion. *Br J Cancer* 1994; 69: 858-62

- 18 Planting ASTh, **Schellens JHM**, Goey SH, Van der Burg MEL, De Boer-Dennert M, Stoter G, Verweij J. Weekly high-dose cisplatin in malignant pleural mesothelioma. *Ann Oncol* 1994; 5: 373-74
- 19 **Schellens JHM**, Planting ASTh, Van Acker BAC, Loos W, De Boer-Dennert M, Van der Burg MEL, Koier I, Krediet R, Stoter G, Verweij J. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. *J Nat Cancer Inst* 1994; 86: 906-12
- 20 **Schellens JHM**, Verweij J, Planting ASTh, De Boer-Dennert M, Van der Burg MEL, Stoter G, Ma J. Optimised sample preparation for measurement of cisplatin-DNA-adducts in WBC. *Contributions to Oncology* 1994; 49: 66-71
- 21 **Schellens JHM**, De Bont-Krootjes BBH, Kolker HJ, Stoter G, Ma J. Cisplatin resistant subline of a human ovarian cancer cell line. *Contributions to Oncology* 1994; 49: 88-94
- 22 Van Warmerdam LJC, Verweij J, Rosing H, **Schellens JHM**, Beijnen JH. Limited sampling models for Topotecan pharmacokinetics. *Ann Oncol* 1994; 5: 259-64
- 23 Verweij J, Aamdal S, **Schellens JHM**, Koier I, Lund B for the EORTC Early Clinical Trials Group: Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. *Oncology Res* 1994; 6: 519-23
- 24 Ma J, Verweij J, Planting ASTh, De Boer-Dennert M, Van Ingen HE, Van der Burg MEL, Stoter G, **Schellens JHM**. Current samples handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. *Br J Cancer* 1995; 71: 512-17
- 25 Planting ASTh, Van der Burg MEL, Goey SH, **Schellens JHM**, Van den Bent MJ, De Boer-Dennert M, Stoter G, Verweij J. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. *Ann Oncol* 1995; 6: 613-15
- 26 Van Meerten E, Verweij J, **Schellens JHM**. Antineoplastic agents: Drug interactions of clinical significance. *Drug safety* 1995; 12: 168-82
- 27 Van Warmerdam LJC, Verweij J, **Schellens JHM**, Rosing H, Davies BE, De Boer-Dennert M, Maes RAA, Beijnen JH. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. *Cancer Chemother Pharmacol* 1995; 35: 237-45
- 28 Verweij J, **Schellens JHM**. Topoisomerase I inhibition: a new target or new missiles? *Ann Oncol* 1995; 6: 102-04
- 29 Creemers GJ, Gerrits CHJ, **Schellens JHM**, Planting ASTh, Van der Burg MEL, Loos WJ, Van Beurden VM, De Boer-Dennert M, Hartevelde M, Hudson I, Stoter G, Verweij J. Phase II and pharmacologic study on topotecan administered as a 21-days continuous infusion to patients with colorectal cancer. *J Clin Oncol* 1996; 14: 2540-45
- 30 De Wit R, Beijnen JH, Van Tellingen O, **Schellens JHM**, De Boer-Dennert M, Verweij J. Pharmacokinetic profile and clinical efficacy of a once daily ondansetron suppository in cyclophosphamide induced emesis: a double blind comparative study with ondansetron tablets. *Br J Cancer* 1996; 74: 323-32
- 31 Gerrits CJH, Creemers GJ, **Schellens JHM**, Wissel P, Planting ASTh., Kunka R, Selinger K., de Boer-Dennert M., Marijnen Y., Hartevelde M., Verweij J. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. *Br J Cancer* 1996; 73: 744-50
- 32 Ma J, Verweij J, Planting ASTh, Kolker HJ, Loos WJ, De Boer-Dennert M, Van der Burg MEL, Stoter G and **Schellens JHM**. Docetaxel (Taxotere®) and paclitaxel (Taxol®) inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leucocytes (WBC). *Cancer Chemother Pharmacol* 1996; 37: 382-84
- 33 Ma J, Stoter G, Verweij J, **Schellens JHM**. Comparison of ethanol plasma protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. *Cancer Chemother Pharmacol* 1996; 38: 391-94
- 34 Loos WJ, Stoter G, Verweij J, **Schellens JHM**. Sensitive high-performance liquid chromatographic

fluorescence assay for the quantitation of topotecan (SKF 104864-A) and lactone ring-opened product (hydroxy acid) in human plasma and urine. *J Chromatogr B: Biomedical applications* 1996; 678: 309-15

- 35 Planting ASTh, Van der Burg MEL, Goey SH, **Schellens JHM**, Vecht Ch, De Boer-Dennert M, Stoter G, Verweij J. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma. *Eur J Cancer* 1996; 32A: 2026-28
- 36 **Schellens JHM**, Creemers GJ, Beijnen JH, Rosing H, De Boer-Dennert M, McDonald M, Davies B, Verweij J. Bioavailability and pharmacokinetics of oral topotecan, a new topoisomerase I inhibitor. *Br J Cancer* 1996; 73: 1268-71
- 37 **Schellens JHM**, Jianguo M, Planting ASTh, Van der Burg MEL, Van Meerten E, De Boer-Dennert M, Schmitz PIM, Stoter G, Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumour response in patients with solid tumours. *Br J Cancer* 1996; 73: 1569-75
- 38 **Schellens JHM**, Pronk LC, Verweij J. Emerging drug treatments for solid tumours. *Drugs* 1996; 51: 45-72
- 39 Van de Vrie W, **Schellens JHM**, Loos WJ, Kolker HJ, Verweij J, Stoter G, Durante NMC, Eggermont AMM. Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. *J Cancer Res Clin Oncol* 1996; 122: 403-08
- 40 Van der Bent MJ, **Schellens JHM**, Sillevius Smitt PAE, Vecht CJ. De plaats van chemotherapie bij hersentumoren. *Ned Tijdschr Geneesk* 1996; 140: 702-06
- 41 Van Warmerdam LJC, Creemers GJ, Rodenhuis S, Rosing H, De Boer-Dennert M, **Schellens JHM**, Ten Bokkel Huinink WW, Davies BE, Maes RAA, Verweij J, Beijnen JH. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. *Cancer Chemother Pharmacol* 1996; 38: 254-60
- 42 Lazo JS, Sebti SM, **Schellens JH**. Bleomycin. *Cancer Chemother Biol Response Modif* 1996; 16: 39-47
- 43 Baille P, Bruno R, **Schellens JHM**, Webster LK, Millward M, Verweij J, Montay G. Optimal sampling strategies for Bayesian estimation of docetaxel (taxotere) clearance. *Clin Cancer Res* 1997; 3: 1535-38
- 44 Creemers GJ, Gerrits CJH, Eckardt JR, **Schellens JHM**, Burris HA, Planting ASTh, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD. Phase I and pharmacologic study of oral topotecan administered twice daily for 21-days to adult patients with solid tumors. *J Clin Oncol* 1997; 15: 1087-93
- 45 Crul M, **Schellens JHM**, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA-repair. *Cancer Treatm Rev* 1997; 23: 341-66
- 46 Gerrits CJH, De Jonge MJA, **Schellens JHM**, Stoter G, Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. *Br J Cancer* 1997; 76: 952-62
- 47 Gerrits CJH, **Schellens JHM**, Creemers GJ, Wissel P, Planting ASTh, Pritchard JF, DePee S, De Boer-Dennert M, Harteveld M and Verweij J. The bioavailability of oral GI147211, a new topoisomerase I inhibitor. *Br J Cancer* 1997; 76: 946-51
- 48 Loos WJ, Sparreboom A, Stoter G, Verweij J, Nooter K, **Schellens JHM**. Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. *J Chromatogr Biomed Appl* 1997; 694: 435-41
- 49 Planting ASTh, Kho S, Van der Burg M, Goey SH, **Schellens JHM**, Van den Bent M, Van der Gaast A, De Boer-Dennert M, Stoter G, Verweij J. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer. *Cancer Chemother Pharmacol* 1997; 40: 347-52
- 50 Pronk LC, **Schellens JHM**, Planting ASTh, Van den Bent MJ, Hilkens PHE, Van der Burg MEL, De Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. *J Clin Oncol* 1997; 3: 1071-79
- 51 **Schellens JHM**, Van de Vrie W, Loos WJ, Kolker HJ, Verweij J, Stoter G, Durante NMC, Eggermont AMM. Pharmacokinetics of the MDR-converting drug dexniguldipine and its pyridine metabolite M-1, in plasma, tumor and renal tissue in tumor bearing Wag/rijrats. *Cancer Chemother Pharmacol* 1997; 41: 48-52

- 52 Veenhuizen R, Oppelaar H, Ruevekamp M, **Schellens JHM**, Dalesio O, Stewart F. Does tumour uptake of Foscan determine PDT efficacy? *Int J Cancer* 1997; 73: 236-39
- 53 Welters MJP, Maliepaard M, Jacobs-Bergmans AJ, Baan RA, **Schellens JHM**, Ma J, Van der Vijgh WJF, Braakhuis BJM, Fichtinger-Schepman AMJ. Improved ³²P-postlabelling assay for the quantification of the major platinum-DNA adducts. *Carcinogenesis* 1997; 18: 1767-74
- 54 Crommentuyn KML, **Schellens JHM**, Van den Berg JD, Beijnen JH. In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. *Cancer Treatm Rev* 1998; 24: 345-66
- 55 Gerrits CJH, Burris H, **Schellens JHM**, Eckardt JR, Planting ASTh, Van der Burg MEL, Rodriguez GI, Loos WJ, Van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J. Oral topotecan given once or twice daily for ten days: a phase I and pharmacology study in adult patients with solid tumors. *Clin Cancer Res* 1998; 4: 1153-58
- 56 Gerrits CJH, Burris H, **Schellens JHM**, Planting ASTh, Van der Burg MEL, Rodriguez GI, Van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J, Von Hoff DD. Five days of oral topotecan (Hycamtin®), a phase I and pharmacologic study in adult patients with solid tumors. *Eur J Cancer* 1998; 34: 1030-35
- 57 Herben VMM, Mazee D, Van Zomeren DM, Zeedijk S, Rosing H, **Schellens JHM**, Ten Bokkel Huinink WW, Beijnen JH. Sensitive determination of the carboxylate and lactone forms of the novel antitumor drug irinotecan and its active metabolite in plasma by high-performance liquid chromatography. *J Liq Chromatogr Rel Tech* 1998; 21: 1541-58
- 58 Herben VMM, Ten Bokkel Huinink WW, **Schellens JHM**, Beijnen JH. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. *Pharmacy World & Sci* 1998; 20: 161-72
- 59 Kuiper RA, **Schellens JHM**, Blijham GH, Beijnen JH, Voest EE. Clinical research on antiangiogenic therapy. *Pharmacol Res* 1998; 27: 1-16
- 60 Ma J, Maliepaard M, Kolker HJ, Verweij J, **Schellens JHM**. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. *Cancer Chemother Pharmacol* 1998; 41: 186-92
- 61 Ma J, Maliepaard M, Nooter K, Boersma AWM, Verweij J, Stoter G, **Schellens JHM**. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. *Cancer Chemother Pharmacol* 1998; 41: 307-16
- 62 Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter, **Schellens JHM**. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. *Br J Cancer* 1998; 77: 1645-52
- 63 Mackean MJ, Planting ASTh, Twelves C, **Schellens JHM**, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye SB, Verweij J. A phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. *J Clin Oncol* 1998; 16: 2977-85
- 64 Meerum Terwogt JM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, **Schellens JHM**. Co-administration of oral cyclosporin A enables oral therapy with paclitaxel. *Lancet* 1998; 325: 285
- 65 Nannan Panday VR, Van Warmendam LJC, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CHN, **Schellens JHM**, Beijnen JH. Carboplatin dosage formulae can generate inaccurate predictions of carboplatin exposure in carboplatin/paclitaxel combination regimens. *Clin Drug Invest* 1998; 15: 327-35
- 66 Nannan Panday VR, Huizing MT, Van Warmendam LJC, Dubbelman RC, Mandjes I, **Schellens JHM**, Ten Bokkel Huinink WW, Beijnen JH. Pharmacologic study of 3-hour 135 mg/m² paclitaxel in platinum pretreated patients with advanced ovarian cancer. *Pharmacol Res* 1998; 38: 231-36
- 67 Nannan Panday VR, Ten Bokkel Huinink WW, Rosing H, Koopman FJ, Hillebrand MJX, Dubbelman RC, Van Tellingen O, **Schellens JHM**, Beijnen JH. Phase I and pharmacologic study of weekly doxorubicin and 1-hour infusional paclitaxel in patients with advanced breast cancer. *Anti-Cancer Drugs* 1998; 9: 665-73
- 68 Pronk LC, Schrijvers D, **Schellens JHM**, De Bruijn EA, Planting ASTh, Locci-Tonelli D, Bruno R, Verweij J,

- Van Oosterom AT. Phase I study on docetaxel and ifosfamide in patients with advanced solid tumors. *Br J Cancer* 1998; 77: 153-58
- 69 Pronk LC, Schrijvers D, **Schellens JHM**, De Bruijn EA, Planting ASTh, Locci-Tonelli D, Groult V, Verweij J, Van Oosterom AT. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study. *Semin Oncol* 1998; 25: 23-28
- 70 Straathof CSM, Van den Bent MJ, Ma J, Kros JM, Stoter G, Vecht CJ, **Schellens JHM**. The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. *J Neuro-Oncol* 1998; 37: 1-8
- 71 Van den Bent MJ, **Schellens JHM**, Sillevius Smit PAE, Vecht CJ, Loosveld OJL, Ma J, Tijssen CC, Janssen RLH, Kros JM, Verweij J. Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. *Eur J Cancer* 1998 ; 34: 1570-74
- 72 De Graaff M, Maliepaard M, Pluim D, Floot BJ, Slaper-Cortenbach IC, **Schellens JHM**. In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM. *Anticancer Drugs* 1999; 10: 213-18
- 73 Gerrits CJH, **Schellens JHM**, Burris H, Eckardt JR, Planting ASTh, Van den Burg MEL, Rodriguez GI, Loos WJ, Van Beurden V, Hudson I, Von Hoff DD, Verweij J. A comparison of clinical pharmaco-dynamics of different administration schedules of oral topotecan. *Clin Cancer Res* 1999; 5: 69-75
- 74 Herben VMM, Nannan Panday VR, Richel DJ, **Schellens JHM**, Van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, Ten Bokkel Huinink WW. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin and topotecan administered intravenously every 21 days as a first line therapy in patients with advanced ovarian cancer. *J Clin Oncol* 1999; 17: 747-55
- 75 Meerum Terwogt JM, **Schellens JHM**, Ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. *Cancer Treat Rev* 1999; 25: 83-101
- 76 Nannan Panday VR, Ten Bokkel Huinink WW, Vermorcken JB, Rosing H, Koopman FJ, Swart M, **Schellens JHM**, Beijnen JH. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. *Pharmacol Res* 1999; 40: 67-74
- 77 Nannan Panday VR, Van Warmendam LJC, Huizing MT, Rodenhuis S, **Schellens JHM**, Beijnen JH. A single 24-hour plasma sample does not predict the carboplatin-AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen. *Cancer Chemother Pharmacol* 1999; 45: 435-38
- 78 Rosing H, van Zomeren DM, Doyle E, Ten Bokkel WW, **Schellens JHM**, Bult A, Beijnen JH. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. *J Chromatogr B* 1999; 727: 191-203
- 79 Van Zuylen C, **Schellens JHM**, Goey SH, Pronk LC, De Boer-Dennert M, Loos WJ, Stoter G, Ma J, Verweij J. Phase I and pharmacologic study of the arotinoid RP 40-8757 in combination with cisplatin and etoposide in patients with advanced or locally recurrent or metastatic non-small cell lung cancer. *Anti-Cancer Drugs* 1999; 10: 361-68
- 80 Straathof CS, Van den Bent MJ, Loos WJ, Vecht CJ, **Schellens JHM**. The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. *J Neurooncol* 1999; 42: 117-22
- 81 Herben VMM, Rosing H, Ten Bokkel Huinink WW, Van Zomeren DM, Batchelor D, Doyle E, Beusenberg FD, Beijnen JH, **Schellens JHM**. A new oral dosage form of topotecan: bioavailability and effect of food co-administration. *Br J Cancer* 1999; 80: 1380-86
- 82 Herben VMM, **Schellens JHM**, Swart M, Gruia G, Beijnen JH, Ten Bokkel Huinink WW. A phase I and pharmacokinetic study of irinotecan administered as a low dose continuous intravenous infusion over fourteen days in patients with malignant solid tumors. *J Clin Oncol* 1999; 17: 1897-1905
- 83 Herben VMM, Van Gijn R, **Schellens JHM**, Schot M, Lieverst J, Hillebrand MJX, Schoemaker NE, Porro MG, Beijnen JH and Ten Bokkel Huinink WW. A Phase I and pharmacokinetic study of a daily times 5

intravenous bolus schedule of 9-aminocamptothecin in colloidal dispersion formulation in patients with advanced solid tumors. *J Clin Oncol* 1999; 17: 1906-14

- 84 Nannan Panday VR, De Wit R, Schornagel JH, Schot M, Rosing H, Lieverst J, Ten Bokkel Huinink WW, **Schellens JHM**, Beijnen JH. Pharmacokinetics of paclitaxel administered in combination with bleomycin, etoposide and cisplatin in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 1999; 44: 349-53
- 85 Nannan Panday VR, Van Warmendam LJC, Huizing MT, Ten Bokkel Huinink WW, **Schellens JHM**, Beijnen JH. A limited sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. *J Cancer Res Clin Oncol* 1999; 125: 615-20
- 86 Verschraagen M, Koks CHW, **Schellens JHM**, Beijnen JH. P-Glycoprotein system as a determinant of drug interactions: The case of Digoxin - Verapamil. *Pharmacol Res* 1999; 40: 301-06
- 87 Van Tellingen O, Huizing MT, Nannan Panday VR, **Schellens JHM**, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo) non-linear pharmacokinetics of paclitaxel in patients. *Br J Cancer* 1999; 81: 330-35
- 88 Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RCAM, Ruevekamp-Helmers MC, Floot BGJ, **Schellens JHM**. Overexpression of the BCRP/ MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. *Cancer Res* 1999; 59: 4559-63
- 89 Pluim D, Maliepaard M, van Waardenburg RCAM, Beijnen JH, **Schellens JHM**. ³²P-postlabeling assay for the quantification of the major platinum-DNA adducts. *Anal Biochem* 1999; 275: 30-38
- 90 Meerum Terwogt JM, Malingré MM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Koopman FJ, Van Tellingen O, Swart M, **Schellens JHM**. Co-administration of cyclosporin enables oral therapy with paclitaxel. *Clin Cancer Res* 1999; 5: 3379-84
- 91 Ravaud A, Borner M, **Schellens JHM**, Geoffrois L, Schöffski P, Wanders J, Hanauske AR. UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. *Oncology* 1999; 3: 61-63
- 92 Planting AST, **Schellens JHM**, van der Burg MEL, de Boer-Dennert M, Winograd B, Stoter G, Verweij J. Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. *Anti-Cancer Drugs* 1999; 10: 821-27
- 93 Den Brok MWJ, de Gast GC, **Schellens JHM**, Beijnen JH. Targeted toxins. *J Oncol Pharm Practice* 1999; 5: 149-65
- 94 Kerbusch T, Huitema ADR, Ouwerkerk J, Keizer HJ, Mothôt RAA, **Schellens JHM**. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. *Br J Clin Pharmacol* 2000; 49: 555-61
- 95 Kuiper RAJ, Malingré MM, Beijnen JH, **Schellens JH**. Cyclosporine-induced anaphylaxis. *Ann Pharmacother* 2000; 34: 858-61
- 96 Kruijtzter CMF, Verweij J, **Schellens JH**, Beijnen JH, Pronk L, Bo M, Lustig V, van Tinteren H, Mackay M, Ten Bokkel Huinink WW. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands. *Anticancer Drugs* 2000; 11: 249-55
- 97 Huitema AD, Mathot RA, Tibben MM, **Schellens JH**, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. *Clin Pharmacol Ther* 2000; 67: 621-30
- 98 Malingré MM, Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K., Ten Bokkel Huinink WW, Swart M, Lieverst J, **Schellens JH**. Phase I and pharmacokinetic study of oral paclitaxel. *J Clin Oncol* 2000; 18: 2468-75
- 99 Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, Schroeijers AB, van der Kolk DM, Allen JD, Ross DD, van der Valk P, Dalton WS, **Schellens JH**, Scheper RJ. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. *Cancer Res* 2000; 60: 2589-93

- 100 Kruijtzter CM, Beijnen JH, Swart M, **Schellens JH**. Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature. *Cancer Chemother Pharmacol* 2000; 45: 428-31
- 101 Rosing H, Lustig V, van Warmendam LJ, Huizing MT, Ten Bokkel Huinink WW, **Schellens JH**, Rodenhuis S, Bult A, Beijnen JH. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. *Cancer Chemother Pharmacol* 2000; 45: 213-18
- 102 Bardelmeijer HA, van Tellingen O, **Schellens JH**, Beijnen JH. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. *New Anticancer Agents* 2000; 18: 231-41
- 103 Huitema ADR, Doesburg Smits K, Mathôt RAA, **Schellens JHM**, Rodenhuis S, Beijnen JH. The clinical pharmacology of alkylating agents in high-dose chemotherapy. *Anti-Cancer Drugs* 2000; 11: 515-33
- 104 Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, **Schellens JHM**, Schinkel AF. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. *J Natl Cancer Inst* 2000; 92: 1651-56
- 105 Van den Bongard HJGD, Mathôt RAA, Beijnen JH, **Schellens JHM**. Pharmacokinetically guided administration of chemotherapeutic agents. *Clin Pharmacokinet* 2000; 39: 345-67
- 106 **Schellens JHM**, Malingré MM, Kruijtzter CMF, Bardelmeijer HA, van Tellingen O, Schinkel AH, Beijnen JH. Modulation of oral bioavailability of anticancer drugs: From mouse to man. *Eur J Pharmaceut Sci* 2000; 12: 103-10
- 107 Nuijen B, Bouma M, Manada C, Jimeno JM, **Schellens JHM**, Bult A and Beijnen JH. Pharmaceutical development of anticancer agents derived from marine sources. *Anti-Cancer Drugs* 2000; 11: 793-811
- 108 Van Gijn R, Lendfers RRH, **Schellens JHM**, Bult A, Beijnen JH. Dual topoisomerase I/II inhibitors. *J Oncol Pharm Practice* 2000; 6: 92-108
- 109 Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, **Schellens JHM**, van Tellingen O. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. *Clin Cancer Res* 2000; 6: 4416-21
- 110 Malingré MM, **Schellens JHM**, van Tellingen O, Rosing H, Koopman FJ, Duchin K, ten Bokkel Huinink WW, Swart M, Beijnen JH. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. *Anti-Cancer Drugs* 2000; 11: 813-20
- 111 Croockewit A, **Schellens J**, van Bronswijk H, Lekkerkerker JF, Koopmans PP. Surrogate endpoints for new colorectal cancer drugs. *Lancet* 2000; 356: 1771
- 112 Gamucci T, Paridaens R, Heinrich B, **Schellens JH**, Pavlidis N, Verweij J, Sessa C, Kaye S, Roelvink M, Wanders J, Hanauske A. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. *Ann Oncol* 2000; 1: 793-97
- 113 Meerum Terwogt J, van Tellingen O, Nannan Panday VR, Huizing MT, **Schellens JH**, Bokkel Huinink WW, Boschma MU, Giaccone G, Veenhof CH, Beijnen JH. Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. *Anticancer Drugs* 2000; 11: 687-94
- 114 Meerum Terwogt JM, Tibben MM, Welbank H, **Schellens JH**, Beijnen JH. Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry. *Fresenius J Anal Chem* 2000; 366: 298-302
- 115 **Schellens JH**, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. *Ann N Y Acad Sci* 2000; 922: 188-94
- 116 Van Kesteren C, Cvitkovic E, Taamma A, Lopez-Lazaro L, Jimeno JM, Guzman C, Math t RA, **Schellens JH**, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. *Clin Cancer Res* 2000; 6: 4725-32

- 117 Crul M, de Klerk GJ, Beijnen JH, **Schellens JH**. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. *Anticancer Drugs* 2001; 12: 163-84
- 118 Crul M, van den Bongard HJ, Tibben MM, van Tellingen O, Sava G, **Schellens JH**, Beijnen JH. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. *Fresenius J Anal Chem* 2001; 369: 442-45
- 119 Huitema ADR, Mathôt RAA, Tibben MM, **Schellens JHM**, Rodenhuis S, Beijnen JH. Population pharmacokinetics of thio TEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. *Br J Clin Pharmacol* 2001; 51: 61-70
- 120 Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, **Schellens JH**. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. *J Clin Oncol* 2001; 19: 1160-66
- 121 Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, Van De Vijver MJ, Scheper RJ, **Schellens JH**. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res* 2001; 15: 3458-64
- 122 Maliepaard M, van Gastelen MA, Togho A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, **Schellens JH**. Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP Inhibitor GF 120918. *Clin Cancer Res* 2001; 7: 935-41
- 123 Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, **Schellens JH**. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel combination with cyclosporin A. *Cancer Chemother Pharmacol* 2001; 47: 347-54
- 124 Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, **Schellens JH**. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. *Anticancer Drugs* 2001; 12: 351-58
- 125 Meerum Terwogt JM, ten Bokkel Huinink WW, **Schellens JH**, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. *Anticancer Drugs* 2001; 12: 315-23
- 126 Kerbusch Th, de Kraker J, Keizer JH, van Putten WG, Groen HJM, Jansen RLH, **Schellens JHM**, Beijnen JH. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. *Clin Pharmacokinet* 2001; 40: 41-62
- 127 Nuijen B, Bouma M, **Schellens JHM**, Beijnen JH. Progress in the development of alternative pharmaceutical formulations of taxanes. *Invest New Drugs* 2001; 19: 143-53
- 128 Malingré MM, Beijnen JH, **Schellens JHM**. Oral delivery of taxanes. *Invest New Drugs* 2001; 19: 155-62
- 129 Smyth J, Bonnetterre ME, **Schellens J**, Calvert H, Grein G, Wanders J and Hanauske A. Activity of the dolastatin analogue, LU103793, in malignant melanoma. *Ann Oncol* 2001; 12: 509-11
- 130 Cocquyt V, Van Belle S, Reinhardt RR, Cocquyt V, Decramer MLA, O'Brien M, **Schellens JHM**, Borms M, Verbeke L, Van Aelst FJ, De Smet M, Carides AD, Eldridge K, Gert ZJ. Comparison of L-758, 298, a selective neurokinin-1 antagonist, to ondansetron in the prevention of cisplatin-induced emesis. *Eur J Cancer* 2001; 37: 835-42
- 131 **Schellens JHM**, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, Wanders J, Aamdal S, Verweij J, Hanauske AR on behalf of the EORTC Early Clinical Studies Group. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. *Anticancer Drugs* 2001; 12: 583-90
- 132 Malingré MM, **Schellens JHM**, Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Jansen SE, Schot ME, Ten Bokkel Huinink WW, Beijnen JH. The co-solvent cremophor EL limits absorption of orally administered paclitaxel in cancer patients. *Br J Cancer* 2001; 85: 1472-77
- 133 Schoemaker NE, Frigerio E, Fraier D, **Schellens JHM**, Rosing H, Jansen S, Beijnen JH. High-performance

liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma. *J Chromatography B Biomedical Sciences and Applications* 2001; 763: 173-83

- 134 Van Kesteren Ch, Mathôt, López Lázaro L, Cvitkovic E, Taamma A, Jimeno JM, Gtuzman C, **Schellens JHM**, Misset JL, Brain E, Hillebrand MJX, Rosing H, Beijnen JH. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. *Cancer Chemother Pharmacol* 2001; 48: 459-66
- 135 Kemper EM, Jansen B, Brouwer KR, **Schellens JHM**, Beijnen JH, van Tellingen O. Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection. *J Chromatography B* 2001; 759: 135-43
- 136 Ravaud A, Borner M, **Schellens JHM**, Geoffrois L, Schöffski BP, Kroon K, Wanders J, Hanauske AR, Fumoleau P. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. *Eur J Cancer* 2001; 37: 1642-47
- 137 Kerbusch T, Mathôt RAA, Heizer HJ, Ouwerkerk J, Rodenhuis S, **Schellens JHM**, Beijnen JH. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. *Eur J Clin Pharmacol* 2001; 57: 467-77
- 138 Bardelmeijer HA, Ouwehand M, Beijnen JH, **Schellens JH**, van Tellingen O. Determination of cyclosporin A in human and mouse plasma by reversed phase high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl.* 2001; 763: 201-06
- 139 **Schellens JH**, Planting AS, Ma J, Maliepaard M, de Vos A, de Boer Dennert M, Verweij J. Adaptive inpatient dose escalation of cisplatin in patients with advanced head and neck cancer. *Anticancer Drugs* 2001; 12: 667-75
- 140 Sparidans RW, Rosing H, Hillebrand MJ, Lopez-Lazaro L, Jimeno JM, Manzanares I, Van Kesteren C, Cvitkovic E, van Oosterom AT, **Schellens JH**, Beijnen JH. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti cancer agent, in man. *Anticancer Drugs* 2001; 12: 653-66
- 141 Malingre MM, Ten Bokkel Huinink WW, Mackay M, **Schellens JH**, Beijnen JH. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. *Eur J Clin Pharmacol* 2001; 57: 305-07
- 142 Malingre MM, Ten Bokkel Huinink WW, Duchin K, **Schellens JH**, Beijnen JH. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. *Anticancer Drugs* 2001; 12: 591-93
- 143 Sparidans RW, Stokvis E, Jimeno JM, Lopez-Lazaro L, **Schellens JH**, Beijnen JH. Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. *Anticancer Drugs* 2001; 12: 575-82
- 144 Van den Bongard HJ, Mathot RA, Boogerd W, Schornagel JH, Soesan M, **Schellens JH**, Beijnen JH. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. *Cancer Chemother Pharmacol* 2001; 47: 537-40
- 145 Kerbusch T, Mathot RA, Keizer HJ, Kaijser GP, **Schellens JH**, Beijnen JH. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. *Drug Metab Dispos* 2001; 29: 967-75
- 146 Malingre MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst J, **Schellens JH**. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. *Cancer Chemother Pharmacol* 2001; 47: 347-54
- 147 Malingre MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Bokkel Huinink WW, Schot ME, **Schellens JH**. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. *J Clin Oncol* 2001; 19: 1160-66
- 148 Bardelmeijer HA, Ouwehand M, Malingré MM, **Schellens JHM**, Beijnen JH, Van Tellingen O. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. *Cancer Chemother Pharmacol* 2002;

- 149 Terwogt JMM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, Ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, **Schellens JHM**. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. *Cancer Chemother Pharmacol* 2002; 49: 201-10
- 150 Bartelink H, **Schellens JHM**, Verheij M. De gecombineerde toepassing van radiotherapie en chemotherapie bij de behandeling van solide maligne tumoren. *Ned Tijdschr Geneesk* 2002; 146: 504-08
- 151 Bartelink H, **Schellens JH**, Vermeij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. *Eur J Cancer* 2002; 38: 216-22
- 152 **Schellens JHM**, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombrowsky P, Paridaens R, Van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa MC, Selinger K, Wissel PS, Gamucci T, Hanauske AR on behalf of the EORTC Early Clinical Studies Group. Population pharmacokinetic and dynamic analysis of the topoisomerase 1 inhibitor lurtotecan in phase I studies. *Investigational New Drugs* 2002; 20: 83-93
- 153 Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RL, **Schellens JHM**, Van de Vijver. Expression of the breast cancer resistance protein in breast cancer. *Clin Cancer Res* 2002; 8: 1068-74
- 154 Crul M, Mathot RA, Giaccone G, Punt CA, Rosing H, Hillebrand MX, Ando Y, Nishi N, Tanaka M, **Schellens JHM**, Beijnen JH. Population pharmacokinetics of the novel anticancer agent KRN7000. *Cancer Chemother Pharmacol* 2002; 49: 287-93
- 155 Schoemaker NE, Herben VM, de Jong LA, Van Waardenburg RC, Pluim D, Ten Bokkel Huinink WW, Beijnen JH, **Schellens JHM**. Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study. *Anticancer Drugs* 2002; 13: 87-91
- 156 Crul M, De Klerk GJ, Swart M, Weiner L, Palmer PA, Bol CJ, Beijnen JH, **Schellens JHM**. Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors. *Eur J Drug Metab Pharmacokinet* 2002; 27: 61-65
- 157 Van den Bongard HJ, Mathot RA, Van Tellingen O, **Schellens JHM**, Beijnen JH. A population pharmacokinetic model for Cremophor EL using nonlinear mixed-effect modeling: model building and validation. *Br J Clin Pharmacol* 2002; 53: 552-53
- 158 Stokvis E, Rosing H, Lopez-Lazaro L, Jimeno JM, Supko JG, **Schellens JHM**, Beijnen JH. Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by HPLC under basic conditions coupled with positive turbo-ionspray tandem mass spectrometry. *Br J Clin Pharmacol* 2002; 53: 543
- 159 Van Kesteren C, Twelves C, Bowman A, Hoekman K, Lopez-Lazaro L, Jimeno J, Guzman C, Mathot RA, Simpson A, Vermorken JB, Smyth J, **Schellens JHM**, Hillebrand MJ, Rosing H, Beijnen JH. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. *Anticancer drugs* 2002; 13: 381-93
- 160 Beijnen JH, **Schellens JHM**. ET-743 [Commentary]. *Drugs* 2002; 62: 1193-94
- 161 Van den Bongard HJGD, Mathot RAA, Van Tellingen O, **Schellens JHM**, Beijnen JH. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. *Cancer Chemother Pharmacol* 2002; 50: 16-24
- 162 Tibben M, Rademaker-Lakhai JM, Rice JR, Stewart DR, **Schellens JHM**, Beijnen JH. Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. *Anal Bioanal Chem* 2002; 373: 233-36
- 163 Zamboni WC, Gervais AC, Egorin MJ, **Schellens JHM**, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL. Inter- and Intra-tumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin. *Clin Cancer Res* 2002; 8: 2992-99
- 164 Diestra JE, Scheffer GL, Catala II, Maliepaard M, **Schellens JHM**, Scheper RJ, Germa-Lluch JR, Izquierdo M. Frequent expression of the multidrug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumors detected by the BXP-21 monoclonal antibody in paraffin-embedded material. *J*

- 165 Mould DR, Holford NH, **Schellens JH**, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. *Clin Pharmacol Ther* 2002; 71: 334-48
- 166 Allen JD, Van Loevezijn A, Lakhai JM, Van der Valk M, van Tellingen O, Reid G, **Schellens JH**, Koomen GJ, Schinkel AH. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. *Mol Cancer Ther* 2002; 1: 417-25
- 167 Kerbusch T, Mathôt RA, Otten HM, Meesters EW, van Kan HJ, **Schellens JHM**, Beijnen JH. Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. *Pharmacol Toxicol* 2002; 90: 243-45
- 168 Crul M, de Klerk GJ, Swart M, van 't Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, **Schellens JHM**. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. *J Clin Oncol* 2002; 20: 2726-35
- 169 Malingre MM, Hendrix EA, **Schellens JH**, Koks CH, Ribben MM, Challa EE, Beijnen JH. Acute poisoning after oral intake of a toluene-containing paint thinner. *Eur J Pediatr* 2002; 161: 354-55
- 170 Herben VM, Schoemaker E, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, **Schellens JH**, Beijnen JH. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. *Cancer Chemother Pharmacol* 2002; 50: 59-64
- 171 Schoemaker NE, Rosing H, Jansen S, Schoffski P, Rizzo J, **Schellens JH**, Beijnen JH. Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002; 775: 231-37
- 172 Kruijtzter CMF, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, **Schellens JHM**. Increased oral bioavailability of topotecan in combination with the Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp) inhibitor GF120918. *J Clin Oncol* 2002; 20: 2943-50
- 173 Raymond E, ten Bokkel Huinink WW, Taïeb J, Beijnen JH, Faivre SH, Wanders J, Ravic M, Fumoleau P, Armand JP, **Schellens JHM**. Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl-Sulphonamide Inhibiting the Activation of cdk2 and Cyclin E, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Cancer. *J Clin Oncol* 2002; 20: 3508-21
- 174 Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, **Schellens JH**, Beijnen JH, ten Bokkel Huinink WW. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. *Eur J Cancer* 2002; 38: 1615-21
- 175 Schoemaker NE, **Schellens JHM**, ten Bokkel Huinink WW, Beijnen JH. A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. *Br J Cancer* 2002; 87: 608-14
- 176 **Schellens JHM**, Ratain M. Endostatin: Are the 2 Years Up Yet? *J Clin Oncol* 2002; 20: 3758-60
- 177 Kruijtzter CMF, Beijnen JH, **Schellens JHM**. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 (CYP) in the gastrointestinal tract and liver. *The Oncologist* 2002; 7: 516-30
- 178 Kruijtzter CMF, **Schellens JHM**, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathôt RAA, Marcus S, van Tinteren H, Baas P. A phase II and pharmacological study of weekly oral paclitaxel (Paxoral ®) plus cyclosporin A (CsA) in patients with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2002; 20: 4508-16
- 179 Van Kesteren Ch, Mathôt RAA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, **Schellens JHM**. Population pharmacokinetics of the novel anti-cancer agent E7070 during four phase I studies: model building and validation. *J Clin Oncol* 2002; 20: 4065-73

- 180 Van Kesteren Ch, Mathôt RAA, Raymond E, Armand JP, Fumoleau P, Punt C, Ravic M, Wanders J, Beijnen JH, **Schellens JHM**. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anti-cancer agent E7070. *Br J Clin Pharmacol* 2002; 54: 463-71
- 181 Baker SD, Verweij J, Rowinsky EK, Donehower RC, **Schellens J**, Grochow LB, Sparreboom A. Role of Body-Surface Area of Investigational Anticancer Agents in Adults: 1991-2001. *J Natl Cancer Inst* 2002; 94: 1883-88
- 182 Van Kesteren C, Beijnen JH, **Schellens JHM**. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. A review. *Anticancer Drugs* 2002; 13: 989-97
- 183 Crul M, Beerepoort LV, Stokvis E, Vermaat JSP, Rosing H, Beijnen JH, Voest EB, **Schellens JHM**. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518. *Cancer Chemother Pharmacol* 2002; 50: 473-78
- 184 Crul M, van Waardenburg RCAM, Beijnen JH, **Schellens JHM**. DNA-based drug interactions of cisplatin. *Cancer Treatment Rev* 2002; 28: 291-303
- 185 Sparidans RW, Crul M, **Schellens JHM**, Beijnen JH. Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. *J Chromatogr* 2002; 780: 423-30
- 186 Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, **Schellens JHM**, Beijnen JH, van Tellingen O. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. *Cancer Res* 2002; 62: 6158-64
- 187 Stokvis E, Rosing H, Lopes-Lazaro L, Rodriguez I, Jimeno JM, Supko JG, **Schellens JHM**, Beijnen JH. Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry. *J Mass Spectrom* 2002; 37: 992-1000
- 188 Crul M, Schoemaker N, Baas P, Pluim D, Sparidans R, Beijnen JH, Zandwijk N van, **Schellens JH**. Randomized phase I and pharmacological study of 2-weekly gemcitabine and cisplatin in advanced non-small cell lung cancer. *Br J Clin Pharmacol* 2002; 54: 554-55
- 189 Van den Bongard HD, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, **Schellens JH**, Beijnen JH. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. *Anticancer Drugs* 2002; 13: 807-14
- 190 Caponigro F, Dittrich C, Sorensen JB, **Schellens JH**, Duffaud F, Paz Ares L, Lacombe D, de Balincourt C, Fumoleau P. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. *Eur J Cancer* 2002; 38: 70-74
- 191 Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, **Schellens JH**, Egorin MJ, Trump DL, Johnson CS. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase 1 (MEKK-1) expression. *Mol Cancer Ther* 2002; 1: 821-29
- 192 Schoemaker NE, Mathot RA, Schoffski P, Rosing H, **Schellens JH**, Beijnen JH. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. *Cancer Chemother Pharmacol* 2002; 50: 514-17
- 193 Crul M, van Waardenburg RCAM, Bocxe S, van Eijndhoven MAJ, Pluim D, Beijnen JH, **Schellens JHM**. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. *Biochem Pharmacol* 2003; 65: 275-82
- 194 Kruijtzter CMF, Boot H, Beijnen JH, Lochs HL, Parnis FP, Planting ASTh, Pelgrims JMG, Williams R, Mathôt RAA, Rosing H, Schot ME, van Tinteren H, **Schellens JHM**. Weekly oral Paclitaxel as first-line treatment in patients with advanced gastric cancer. *Ann Oncol* 2003; 14: 197-204
- 195 **Schellens JHM**, Planting ASTh, Van Zandwijk N, Ma J, Maliepaard M, van der Burg MEL, de Boer-Dennert M, Van der Gaast A, van den Bent MJ, Verweij J. Adaptive inpatient dose-escalation of Cisplatin in combination with low dose VP16 in patients with non-small cell lung cancer. *Br J Cancer* 2003; 88: 814-21
- 196 Schoemaker NE, Mathôt RAA, Schoffski P, Rosing H, Beijnen JH, **Schellens JHM**. Development of an

optimal pharmacokinetic sampling schedule for rubitecan administration orally in a daily times five schedule. *Cancer Chemother Pharmacol* 2002; 50: 514-17

- 197 Van Kesteren Ch, Mathot RAA, Beijnen JH, **Schellens JHM**. PK-PD modeling and trial design in oncology. *Inv New Drugs* 2003; 21: 225-41
- 198 Van den Brande J, Schoffski P, **Schellens JHM**, Roth A, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken J, Fumoleau P. EORTC Early Clinical studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. *Br J Cancer* 2003; 88: 648-53
- 199 Schoemaker NE, Rosing H, Jansen S, **Schellens JHM**, Beijnen JH. High-Performance Liquid Chromatographic Analysis of the Anticancer Drug Irinotecan (CPT-11) and Its Active Metabolite SN-38 in Human Plasma. *Ther Drug Monit* 2003; 25: 120-24
- 200 Bardelmeijer HA, Oomen IAM, Hillebrand MJX, Beijnen JH, **Schellens JHM**, van Tellingen O. Metabolism of Paclitaxel in Mice. *Anticancer Drugs* 2003; 3: 203-09
- 201 Sparidans RW, Crommentuyn KM, **Schellens JH**, Beijnen JH. Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. *J Chromatogr B Analyt Technol Biomed Life Sci* 2003; 791: 227-33
- 202 Stokvis E, Nan-Offeringa L, Rosing H, López-Lázzaro L, Aceña JL, Miranda E, Lyubimov A, Levine BE, D'Aleo C, **Schellens JHM**, Beijnen JH. Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using couples liquid chromatography and tandem mass spectrometry. *J Mass Spectrom* 2003; 38: 548-54
- 203 Brandon EFA, Raap CD, Meijerman I, Beijnen JH, **Schellens JHM**. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. *Toxicol Applied Pharmacol* 2003; 189: 233-46
- 204 Callies S, de Alwis DP, Harris A, Vasey P, Beijnen JH, **Schellens JH**, Burgess M, Aarons L. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). *Br J Clin Pharmacol* 2003; 56: 46-56
- 205 Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, **Schellens JH**, Van Tellingen. O. Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. *Lab Anim* 2003; 37: 181-87
- 206 Van den Bongard HJ, Pluim D, Waardenburg RC, Mavic M, Beijnen JH, **Schellens JH**. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. *Anticancer Drugs* 2003; 14: 405-10
- 207 Rajendra R, Gounder MK, Saleem A, **Schellens JH**, Ross DD, Bates SE, Sinko P, Rubin EH. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. *Cancer Res* 2003; 63: 3228-33
- 208 Chollet P, Schoffski P, Weigang-Kohler K, **Schellens JH**, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P, EORTC Early Clinical Studies Group. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). *Eur J Cancer* 2003 ; 39: 1264-70
- 209 Terret C, Zanetta S, Roche H, **Schellens JH**, Faber MN, Wanders J, Ravic M, Droz JP; EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG). *Eur J Cancer* 2003; 39: 1097-104
- 210 Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, **Schellens JH**, Schinkel AH, Borst P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). *J Biol Chem* 2003; 278: 23538-44
- 211 Van Kesteren Ch, de Vooght MM, Lopez-Lazaro L, Mathot RA, **Schellens JH**, Jimeno JM, Beijnen JH. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. *Anticancer Drugs* 2003; 14: 487-502
- 212 Sparidans RW, Silvertand L, Dost F, Rothbarth J, Mulder GJ, **Schellens JHM**, Beijnen JH. Simple high-

performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. *Biomed Chromatogr* 2003; 17: 458-64

- 213 Van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, **Schellens JH**, Beijnen JH, Schinkel AH. The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Cancer Res* 2003; 63: 6447-52
- 214 Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, **Schellens JH**. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. *Clin Cancer Res* 2003; 9: 3526-33
- 215 Van Kesteren C, Mathot RA, Beijnen JH, **Schellens JH**. Pharmacokinetic-pharmacodynamic guided trial design in oncology. *Invest New Drugs* 2003; 21: 225-41
- 216 Chollet P, Schoffski P, Weigang-Köhler K, **Schellens JHM**, Cure H, Pavlidis N, Grünwald V, de Boer R, Wanders J, Fumoleau P. Phase II trial with S1 in patients with gastric cancer, treated in first line (an ECSG-EORTC phase II trial). *Eur J Cancer* 2003; 39: 1264-70
- 217 Van den Bongard DHJG, Kemper EM, Van Tellingen O, Rosing H, Mathôt RAA, **Schellens JHM**, Beijnen JH. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. *Anal Biochem* 2004; 324: 11-15
- 218 Brandon EF, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, **Schellens JH**. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. *Invest New Drugs* 2004; 22: 241-51
- 219 Beijnen JH, **Schellens JHM**. Drug Interactions in Oncology. *Lancet Oncology* 2004; 5: 489-96
- 220 Van Waardenburg RC, De Jong LA, Van Delft F, Van Eijndhoven MA, Bohlander M, Bjornsti MA, Brouwer J, **Schellens JH**. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. *Mol Cancer Ther* 2004; 3: 393-402
- 221 Stokvis E, Rosing H, Crul M, Rieser MJ, Heck AJ, **Schellens JH**, Beijnen JH. Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electro-spray tandem mass spectrometry *J Mass Spectrom* 2004; 39: 277-88
- 222 Pluim D, Van Waardenburg RC, Beijnen JH, **Schellens JH**. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. *Cancer Chemother Pharmacol* 2004; 54: 71-78
- 223 Kuppens IE, Boot H, Beijnen JH, **Schellens JH**, Labadie J. Capecitabine induces severe angina-like chest pain. *Ann Intern Med* 2004; 140: 494-95
- 224 Sparidans RW, **Schellens JH**, Lopez-Lazaro L, Jimeno JM, Beijnen JH. Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole. *Biomed Chromatogr* 2004; 18: 16-20
- 225 Van den Bongard HJ, Sparidans RW, Critchley DJ, Beijnen JH, **Schellens JH**. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. *Invest New Drugs* 2004; 22: 151-58
- 226 Zamboni WC, Gervais AC, Egorin MJ, **Schellens JH**, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. *Cancer Chemother Pharmacol* 2004; 53: 329-36
- 227 De Jonge ME, van den Bongard HJ, Huitema AD, Mathot RA, Rosing H, Baas P, van Zandwijk N, Beijnen JH, **Schellens JH**. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. *Clin Cancer Res* 2004; 10: 2237-44

- 228 Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, **Schellens JH**, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. *Clin Infect Dis* 2004; 38: 73-75
- 229 Kerbusch T, Groenewegen G, Mathot RA, Herben VM, Ten Bokkel Huijnk WW, Swart M, Ambaum B, Rosing H, Jansen S, Voest EE, Beijnen JH, **Schellens JH**. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. *Br J Cancer* 2004; 90: 2268-77
- 230 Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, **Schellens JH**, Droz JP. Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. *Clin Cancer Res* 2004; 10: 3386-95
- 231 Rademaker-Lakhai JM, Van den Bongard D, Pluim D, Beijnen JH, **Schellens JH**. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. *Clin Cancer Res* 2004; 10: 3717-27
- 232 Bardelmeijer HA, Ouwehand M, Beijnen JH, **Schellens JHM**, Van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. *Invest New Drugs* 2004; 22: 219-29
- 233 Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvers A, Schornagel JH, Beijnen JH, Fumoleau P, **Schellens JH**. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. *Clin Cancer Res* 2004; 10: 4072-76
- 234 Stokvis E, Nan-Offeringa LG, Ouwehand M, Tibben MM, Rosing H, Schnaars Y, Grigat M, Romeis P, **Schellens JH**, Beijnen JH. Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2004; 18: 1465-71
- 235 Stokvis E, Rosing H, López-Lázaro L, **Schellens JHM**, Beijnen JH. A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. *Biomed Chromotogr* 2004; 18: 403-07
- 236 Stokvis E, Rosing H, López-Lázaro L, **Schellens JHM**, Beijnen JH. Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance. *Biomed Chromotogr* 2004; 18: 400-02
- 237 Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, Van Tellingen O, Borst P, **Schellens JHM**. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. *Cancer Res* 2004; 64: 5804-11
- 238 Rothbarth J, Tollenaar RA, **Schellens JH**, Nortier JW, Kool LJ, Kuppen PJ, Mulder GJ, Van de Velde CJ. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. *Eur J Cancer* 2004; 40: 1812-24
- 239 Calvet L, Santos A, Valent A, Terrier-Lacombe M-J, Opolon P, Merlin J-L, Aubert G, Morizet J, **Schellens JHM**, Bénard J, Vassal G. No topoisomerase I alteration in a neuroblastoma model with *in vivo* acquired resistance to irinotecan. *Br J Cancer* 2004; 91: 1205-12
- 240 Stokvis E, Rosing H, Causon RC, **Schellens JHM**, Beijnen JH. Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection. *J Mass Spectrometry* 2004; 39: 1122-30
- 241 Beumer JH, Rosing H, Hillebrand MJX, Nan-Offringa LGAH, Foley K, Yule SM, Heck AJR, **Schellens JHM**, Beijnen JH. Quantitative determination of the novel anticancer drug E7070 (Indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *Rapid Comm Mass Spectrometry* 2004; 18: 2839-48
- 242 Fracasso PM, Goldstein JL, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VE, Burgess MF, Slapak CA, **Schellens JH**. Phase I study of docetaxel in combination

with the P-glycoprotein inhibitor zosuquidar, in resistant malignancies. *Clin Cancer Res* 2004; 10: 7220-28

- 243 Joerger M, **Schellens JH**, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. *Methods Find Exp Clin Pharmacol* 2004; 26: 531-45
- 244 Schoemaker NE, Kuppens IELM, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP, Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, Gruia G, Mourier A, Sibaud D, Lefebvre P, Beijnen JH, **Schellens JHM**, Ten Bokkel Huinink WW. A randomized phase II multicenter trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. *Br J Cancer* 2004; 91: 1434-41
- 245 Kuppens IE, Beijnen J, **Schellens JH**. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. *Clin Colorectal Cancer* 2004; 4: 163-80
- 246 Frankfort SV, Tulner RR, Knol W, Van Campen JPCM, **Schellens JHM**, Beijnen JH. Prescription error resulting in valproic acid intoxication [Letter to Editor]. *J Am Geriatric Soc* 2004; 52: 2142-43
- 247 De Jonge ME, van den Bongard HJ, Huitema AD, Mathot RA, Rosing H, Baas P, van Zandwijk N, Beijnen JH, **Schellens JH**. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. *Clin Cancer Res* 2004; 10: 2237-44
- 248 Van Waardenburg RC, De Jong LA, Van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, **Schellens JH**. Platinated DNA adducts enhance poisoning of DNA topoisomerase by camptothecin. *J Biol Chem* 2004; 279: 54502-09
- 249 Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, **Schellens JH**. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. *Cancer Chemother Pharmacol* 2005; 55: 263-70
- 250 De Jonge ME, Huitema AD, **Schellens JHM**, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaption: a review. *Clin Pharmacokinet* 2005; 44: 147-73
- 251 Van Tellingen O, Bardelmeijer A, Buckle T, Ouwehand M, Beijnen JH, **Schellens JHM**. Cannulation of the jugular vein in mice. *Lab Anim* 2005; 39: 130
- 252 **Schellens JHM**. Challenges of oral chemotherapy. *Clin Adv Hematol Oncol* 2005; 3: 99-100
- 253 Beumer JH, **Schellens JHM**, Beijnen JH. Hepatotoxicity and metabolism of trabectedin. *Pharmacol Res* 2005; 51: 391-98
- 254 Maat MMR, Beijnen JH, **Schellens JHM**, Mulder JW. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. *J Infect* 2005; 50: 262-64
- 255 Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, De Reike TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, **Schellens JH**. Phase I clinical and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer. *Clin Cancer Res* 2005; 11: 1854-62
- 256 De Jonge ME, Huitema ADR, **Schellens JHM**, Rodenhuis S, Beijnen JH. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. *Br J Clin Pharmacol* 2005; 59: 1365-2125
- 257 Van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, **Schellens JHM**. Semi-physiological model describing the hematological toxicity of the anti-cancer agent Indisulam. *Invest New Drugs* 2005; 23: 225-34
- 258 Kuppens IE, Bosch TM, Van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, **Schellens JH**. Oral bio-availability of docetaxel in combination with OC144-093 (ONT-093). *Cancer Chemother Pharmacol* 2005; 55: 72-78
- 259 Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, **Schellens JHM**, Beijnen JH, Smits PH, Meijerman I. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. *Am J Pharmacogenomics* 2005; 5: 123-31

- 260 Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, **Schellens JHM**. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. *Cancer Res* 2005; 65: 2577-82
- 261 Bardelmeijder HA, Roelofs ABGH, Hillebrand MJX, Beijnen JH, **Schellens JHM**, Van Tellingen O. Metabolism of docetaxel in mice. *Cancer Chemother Pharmacol* 2005; 56: 299-306
- 262 Brandon EFA, Van Ooijen RD, Sparidans RW, Lopez Lazaro L, Heck AJR, Beijnen JH, **Schellens JHM**. Structure elucidation of apidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. *J Mass Spectrom* 2005; 40: 821-31
- 263 Kappelhoff BS, Huiteman ADR, Mairuhu ATA, **Schellens JHM**, Beijnen JH. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. *Anticancer Drugs* 2005; 16: 627-30
- 264 Van Herwaarden AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CM, **Schellens JHM**, Beijnen JH, Schinkel AH. Midazolam and cyclosporin A metabolism in transgenic mice with liver-specific expression of human CYP3A4. *Drug Metab Dispos* 2005; 33: 892-95
- 265 Sesink A, Arts I, de Boer V, Breedveld P, **Schellens JHM**, Hollman P, Russel F. Breast Cancer Resistance Protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. *Mol Pharmacol* 2005; 67: 1999-2006
- 266 Brouwers EEM, Tibben MM, Joerger M, Van Tellingen O, Rosing H, **Schellens JHM**, Beijnen JH. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. *Anal Bioanal Chem* 2005; 382: 1484-90
- 267 Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, **Schellens JHM**. Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer. *Invest New Drugs* 2005; 23: 429-36
- 268 Mohrmann K, van Eijndhoven MA, Schinkel AH, **Schellens JHM**. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). *Cancer Chemother Pharmacol* 2005; 56: 344-50
- 269 Kuppens IE, Breedveld P, Beijnen JH, **Schellens JHM**. Modulation of oral drug bioavailability. *Cancer Invest* 2005; 23: 443-64
- 270 Appels NM, van Maanen MJ, Rosing H, **Schellens JH**, Beijnen JH. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2005; 19: 2187-92
- 271 Beumer JH, Hillebrand MJ, Pluim D, Rosing H, Foley K, Yule SM, **Schellens JH**, Beijnen JH. Human metabolism of [(14)C] indisulam following i.v. infusion in cancer patients. *Invest New Drugs* 2005; 23: 317-30
- 272 Brandon EF, Meijerman I, Klijn JS, den Arend D, Sparidans RW, Lazaro LL, Beijnen JH, **Schellens JH**. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. *Anticancer Drugs* 2005; 16: 935-43
- 273 Joerger M, Huitema AD, Meenhorst PL, **Schellens JH**, Beijnen JH. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. *Cancer Chemother Pharmacol* 2005; 55: 488-96
- 274 Kuppens IE, van Maanen MJ, Rosing H, **Schellens JH**, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. *Biomed Chromatogr* 2005; 19: 355-61
- 275 Lekkerkerker JF, Schobben AF, van Dissel JT, Hekster YA, Hoes AW, Mulder GJ, Neef C, Peeters MF, van Ree JM, Rosmalen CF, Schellekens H, **Schellens JH**, Silberbusch J. [Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression]. *Ned Tijdschr*

Geneeskd 2005; 149: 1870-71

- 276 Rademaker-Lakhai JM, Crul M, Pluim D, Sparidans RW, Baas P, Beijnen JH, Zandwijk N, **Schellens JH**. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. *Anticancer Drugs* 2005; 16: 1029-36
- 277 Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A, Solanki B, Beijnen JH, **Schellens JH**. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. *Br J Cancer* 2005; 93: 1222-29
- 278 Siegel-Lakhai WS, Beijnen JH, **Schellens JH**. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). *Oncologist* 2005; 10: 579-89
- 279 Vink SR, **Schellens JH**, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. *Invest New Drugs* 2005; 23: 279-86
- 280 Appels NM, Beijnen JH, **Schellens JH**. Development of farnesyl transferase inhibitors: a review. *Oncologist* 2005; 10: 565-78
- 281 Brandon EFA, Sparidans RW, Guijt KJ, Löwenthal S, Meijerman I, Beijnen JH, **Schellens JHM**. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis^R, Trabectedin^R), a novel marine anti-cancer drug. *Invest New Drugs* 2006; 24: 3-14
- 282 Vainchtein LD, Thijssen B, Stokvis E, Rosing H, **Schellens JHM**, Beijnen JH. A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using coupled liquid chromatography and tandem mass spectrometry. *BioMed Chromatogr* 2006; 20: 139-48
- 283 Appels NMGM, Kien-On T, Rosing H, **Schellens JHM**, Beijnen JH. A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors. *Biomed Chromatogr* 2006; 20: 161-65
- 284 Sparidans RW, Dost F, Crommentuyn KML, Huitema ADR, **Schellens JHM**, Beijnen JH. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. *Biomed Chromatogr* 2006; 20: 72-76
- 285 Bosch TM, Meijerman I, Beijnen JH, **Schellens JHM**. Genetic polymorphisms of drug metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer. *Clin Pharmacokinet* 2006; 45: 253-85
- 286 Brandon EFA, Bosch TM, Deenen MJ, Levink R, Van der Wal, Van Meerveld JBM, Bijl M, JH Beijnen, **Schellens JHM**, Meijerman I. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. *Toxicol Appl Pharmacol* 2006; 211: 1-10
- 287 Engwegen JYMN, Helgason HH, Cats A, Harris N, Bonfrer JMG, **Schellens JHM**, Beijnen JH. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. *World J Gastroenterol* 2006; 12: 1536-44
- 288 Joerger M, Huitema ADR, Van den Bongard HJGD, **Schellens JHM**, Beijnen JH. Quantitative impact of gender, age, liver function and body size on the population pharmacokinetics of paclitaxel in solid tumor patients. *Clin Cancer Res* 2006; 12: 2150-57
- 289 Breedveld P, Beijnen JH, **Schellens JHM**. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. *Trends Pharmacol Sci* 2006; 27: 17-24
- 290 Engwegen JYMN, Gast MCW, **Schellens JHM**, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. *Trends Pharmacol Sci* 2006; 27: 251-59
- 291 Bosch TM, Deenen M, Pruntel R, Smits PHM, **Schellens JHM**, Beijnen JH, Meijerman I. Screening for polymorphisms in the PXR gene in a Dutch population. *Eur J Clin Pharmacol* 2006; 62: 395-99

- 292 Appels NM, Rosing H, Stephens TC, **Schellens JH**, Beijnen JH. Quantification of Farnesylmethylcysteine in Lysates of Peripheral Blood Mononuclear Cells Using Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry: Pharmacodynamic Assay for Farnesyl Transferase Inhibitors. *Anal Chem* 2006; 78: 2617-22
- 293 Appels NM, Rosing H, Stephens TC, Hughes A, **Schellens JH**, Beijnen JH. Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. *Anal Biochem* 2006; 352: 33-40
- 294 Beumer JH, Beijnen JH, **Schellens JH**. Mass balance studies, with a focus on anticancer drugs. *Clin Pharmacokinet* 2006; 45: 33-58
- 295 Hoebbers FJ, Pluim D, Verheij M, Balm AJ, Bartelink H, **Schellens JH**, Begg AC. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). *Int J Cancer* 2006; 119: 750-56
- 296 Liedert B, Pluim D, **Schellens J**, Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. *Nucleic Acids Res* 2006; 34: 47
- 297 Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, **Schellens JH**. Relationship between cisplatin administration and the development of ototoxicity. *J Clin Oncol* 2006; 24: 918-24
- 298 Sparidans RW, Bosch TM, Jorger M, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. *J Chromatogr B* 2006; 839: 45-53
- 299 Vink SR, Lagerwerf S, Mesman E, **Schellens JH**, Begg AC, van Blitterswijk WJ, Verheij M. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. *Clin Cancer Res* 2006; 12: 1615-22
- 300 Bosch TM, Doodeman VD, Smits PH, Meijerman I, **Schellens JH**, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a dutch population. *Mol Diagn Ther* 2006; 10: 175-85
- 301 Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, **Schellens JH**, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. *Br J Clin Pharmacol* 2006; 62: 71-80
- 302 Zandvliet AS, Copalu W, **Schellens JH**, Beijnen JH, Huitema AD. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. *Drug Metab Dispos* 2006; 34: 1041-46
- 303 Vlaming MLH, Mohrmann K, Wagenaar E, De Waart DR, Oude Elferink RPJ, Lagas JS, Van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, **Schellens JHM**, Schinkel AH. Carcinogen and anti-cancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. *J Pharmacol Exp Ther* 2006; 318: 319-27
- 304 Van den Broek I, Sparidans RW, Huitema AD, **Schellens JH**, Beijnen JH. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. *J Chromatogr B* 2006; 837: 49-58
- 305 Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, **Schellens JH**. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. *Eur J Clin Pharmacol* 2006; 62: 681-84
- 306 Van den Berg JH, Beijnen JH, Balm AJ, **Schellens JH**. Future opportunities in preventing cisplatin induced ototoxicity. *Cancer Treat Rev* 2006; 32: 390-97
- 307 Meijerman I, Beijnen JH, **Schellens JHM**. Herb-drug interactions in oncology: focus on mechanisms of induction. *Oncologist* 2006; 11: 742-52
- 308 Brandon EF, Sparidans RW, van Ooijen RD, Meijerman I, Lazaro LL, Manzanares I, Beijnen JH,

- Schellens JH.** In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. *Invest New Drugs* 2006; 24: 3-24
- 309 Joerger M, Huitema ADR, Boogerd W, Van der Dande JJ, **Schellens JHM**, Beijnen JH. Interactions of serum albumin, valproic, acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. *Rev Pharmacool Toxicol* 2006; 99: 133-40
- 310 Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, **Schellens JH.** Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel. *Clin Cancer Res* 2006; 12: 5786-93
- 311 Zandvliet AS, **Schellens JH**, Copalu W, Beijnen JH, Huitema AD. A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam. *J Pharmacokinet Pharmacodyn* 2006; 33: 543-70
- 312 Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, **Schellens JH**, and Beijnen JH. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. *Biomed Chromatogr* 2006; 20: 72-76
- 313 Kuppens IE, Dansin E, Boot H, Feger C, Assadourian S, Bonnetterre ME, Beijnen JH, **Schellens JH**, Bonnetterre J. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. *Clin Cancer Res* 2006; 12: 3774-81
- 314 Boekhout AH, Beijnen JH, **Schellens JH.** Symptoms and treatment in cancer therapy-induced early menopause. *Oncologist* 2006; 11: 641-54
- 315 Ekhart C, De Jonge ME, Huitema ADR, **Schellens JHM.** Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. *Clin Cancer Res* 2006; 12: 6502-08
- 316 Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, **Schellens JH**, Beijnen JH. Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. *Biomed Chromatogr* 2006; 20: 671-73
- 317 Gast MC, Bonfrer JM, van Dulken EJ, de Kock L, Rutgers EJ, **Schellens JH**, Beijnen JH. SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. *Cancer Biomark* 2006; 2: 235-48
- 318 Veltkamp SA, Hillebrand MJ, Rosing H, Jansen RS, Wickremsinhe ER, Perkins EJ, **Schellens JH**, Beijnen JH. Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. *J Mass Spectrom* 2006; 41: 1633-42
- 319 Triesscheijn M, Baas P, **Schellens JH**, Stewart FA. Photodynamic therapy in oncology. *Oncologist* 2006; 11: 1034-44
- 320 Siegel-Lakhai WS, Crul M, De Porre P, Zhang S, Chang I, Boot H, Beijnen JH, **Schellens JH.** Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. *J Clin Oncol* 2006; 24: 4558-64
- 321 Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Hillebrand MJ, **Schellens JH**, Beijnen JH. Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. *J Mass Spectrom* 2006; 41: 1268-76
- 322 Helgason HH, Kruijtzter CM, Huitema AD, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, **Schellens JH.** Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. *Br J Cancer* 2006; 95: 794-800
- 323 Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, **Schellens JH**, Beijnen JH. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. *J Mass Spectrom* 2006; 41: 1268-76

- 324 Vink SR, **Schellens JH**, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M. Phase I and pharmacokinetic study of combined treatment with perfosine and radiation in patients with advanced solid tumours. *Radiother Oncol* 2006; 80: 207-13
- 325 Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, **Schellens JH**. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. *Br J Cancer* 2006; 95: 729-34
- 326 Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, **Schellens JH**. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. *Cancer Chemother Pharmacol* 2007; 59: 43-50
- 327 Beumer JH, Buckle T, Ouwehand M, Franke NE, Lopez-Lazaro L, **Schellens JH**, Beijnen JH, van Tellingen O. Trabectedin (ET-743, Yondelistrade mark) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. *Invest New Drugs* 2007; 25: 1-7
- 328 Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, **Schellens JH**. The effect of low pH on Breast Cancer Resistance Protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic Acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. *Mol Pharmacol* 2007; 71: 240-49
- 329 Vainchtein LD, Rosing H, Mirejovsky D, Lenaz L, **Schellens JH**, Beijnen JH. Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer. *J Pharm Biomed Anal* 2007; 43: 285-92
- 330 Sparidans RW, Lagas JS, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 855: 200-10
- 331 Van den Broek I, Sparidans RW, **Schellens JH**, Beijnen JH. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: Measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 854: 245-59
- 332 Keizer RJ, Huitema AD, Damen CW, **Schellens JH**, Beijnen JH. The pharmacokinetics of monoclonal antibodies. *Ned Tijdschr Geneesk* 2007; 151: 683-88
- 333 Brouwers EE, Tibben MM, Rosing H, **Schellens JH**, Beijnen JH. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. *Rapid Commun Mass Spectrom* 2007; 21: 1521-30
- 334 Oostendorp RL, Beijnen JH, **Schellens JH**, Tellingen OV. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. *Biomed Chromatogr* 2007; 21: 747-54
- 335 Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorcken JB, Strocchi E, Martoni A, Sorio R, Sleenboom HP, Izquierdo MA, Jodrell DI, Calvert AH, Boddy A, Hollema H, Fety R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Tranchand B, Schrijvers AH, Beijnen JH, **Schellens JH**. Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG. *Br J Clin Pharmacol* 2007; 63: 505
- 336 Brouwers EE, Huitema AD, Bakker EN, Douma JW, Schimmel KJ, van Weringh G, de Wolf PJ, **Schellens JH**, Beijnen JH. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. *Int Arch Occup Environ Health* 2007; 80: 689-99
- 337 Meijerman I, Sanderson LM, Smits PH, Beijnen JH, **Schellens JH**. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. *Drug Metab Rev* 2007; 39: 45-60
- 338 Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, **Schellens JH**. A Phase I, Randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. *Clin Cancer Res* 2007; 13: 3276-85

- 339 Zandvliet AS, Huitema AD, Copalu W, Yamada Y, Tamura T, Beijnen JH, **Schellens JH**. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. *Clin Cancer Res* 2007; 13: 2970-76
- 340 Harmsen S, Meijerman I, Beijnen JH, **Schellens JH**. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. *Cancer Treat Rev* 2007; 33: 369-80
- 341 Bosch TM, Bakker R, **Schellens JH**, Cats A, Smits PH, Beijnen JH. Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. *Mol Diagn Ther* 2007; 11: 105-08
- 342 **Schellens JH**, Beijnen JH. Management recommendations in patients with methotrexate intoxication. *Ned Tijdschr Geneesk* 2007; 151: 337-41
- 343 Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, **Schellens JH**. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. *Invest New Drugs* 2007; 25: 327-34
- 344 Sparidans RW, Prins JM, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. *Biomed Chromatogr* 2007; 21: 621-27
- 345 Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, **Schellens JH**, Voest EE, Beijnen JH. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. *Lab Invest* 2007; 87: 161-72
- 346 Kemper EM, van Kan HJ, Speelman P, de Gans K, Beijnen JH, **Schellens JH**. Severe phenytoin intoxication in patients with hypoalbuminaemia. *Ned Tijdschr Geneesk* 2007; 151: 138-41
- 347 Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, **Schellens JH**. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. *Cancer Chemother Pharmacol* 2007; 60: 523-33
- 348 **Schellens JH**. Capecitabine. *Oncologist* 2007; 12: 152-55
- 349 Van Erp NP, Oostendorp RL, Guchelaar HJ, **Schellens JH**, Gelderblom H. Is rectal administration an alternative route for imatinib? *Cancer Chemother Pharmacol* 2007; 60: 623-24
- 350 Vink SR, van Blitterswijk WJ, **Schellens JH**, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. *Cancer Treat Rev* 2007; 33: 191-202
- 351 Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, **Schellens JH**, Rodenhuis S. Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. *Invest New Drugs* 2007; 25: 279-81
- 352 Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, **Schellens JH**. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. *Cancer Chemother Pharmacol* 2007; 60: 635-42
- 353 Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, **Schellens JH**. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. *Cancer Chemother Pharmacol* 2007; 59: 855-60
- 354 Kuppens IE, Witteveen PO, Schot M, Schuessler VM, Daehling A, Beijnen JH, Voest EE, **Schellens JH**. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. *Invest New Drugs* 2007; 25: 227-35
- 355 Triesscheijn M, Ruevekamp M, Out R, Van Berkel TJ, **Schellens J**, Baas P, Stewart FA. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men. *Cancer Chemother Pharmacol* 2007; 60: 113-22
- 356 Beumer JH, Rademaker-Lakhai JM, Rosing H, Hillebrand MJ, Bosch TM, Lopez-Lazaro L, **Schellens**

- JH**, Beijnen JH. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. *Cancer Chemother Pharmacol* 2007; 59: 825-37
- 357 Brandon EF, Sparidans RW, van Ooijen RD, Meijerman I, Lazaro LL, Manzanares I, Beijnen JH, **Schellens JH**. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. *Invest New Drugs* 2007; 25: 9-19
- 358 Siegel-Lakhai WS, Beijnen JH, Vervenne WL, Boot H, Keessen M, Versola M, Koch KM, Smith DA, Pandite L, Richel DJ, **Schellens JH**. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/ leucovorin (FOLFOX4) in patients with solid tumors. *Clin Cancer Res* 2007; 13: 4495-502
- 359 Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van hal G, Beijnen JH, **Schellens JH**, Voest EE. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C β -inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. *Clin Cancer Res* 2007; 13: 4474-81
- 360 Vainchtein LD, Rosing H, Maier A, Fiebig HH, **Schellens JH**, Beijnen JH. Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 856: 261-66
- 361 Broker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, **Schellens JH**, Giaccone G. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. *Clin Cancer Res* 2007; 13: 3906-12
- 362 Vainchtein LD, Rosing H, Thijssen B, **Schellens JH**, Beijnen JH. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluoro-deoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007; 21: 2312-22
- 363 Marchetti S, Mazzanti R, Beijnen JH, **Schellens JH**. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glyco-protein). *Oncologist* 2007; 12: 927-41
- 364 Marchetti S, **Schellens JH**. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. *Br J Cancer* 2007; 97: 577-81
- 365 Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, **Schellens JH**. Population pharmacokinetics and pharmacodynamics of Paclitaxel and Carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. *Clin Cancer Res* 2007; 13: 6410-18
- 366 Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, **Schellens JH**, Beijnen JH, Vermorken JB. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. *Br J Clin Pharmacol* 2007; 64: 622-33
- 367 De Kogel CE, **Schellens JH**. Imatinib. *Oncologist* 2007; 12: 1390-94
- 368 **Schellens JH**. Looking back at EACPT 2007. *Basic Clin Pharmacol Toxicol* 2007; 101: 393-94
- 369 Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, **Schellens JH**. In vitro transport of gimatecan (7-t-butoxyiminomethyl-camptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. *Mol Cancer Ther* 2007; 6: 3307-13
- 370 Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, **Schellens JH**, EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer

patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 2007; 46: 1051-68

- 371 Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, **Schellens JH**, Beijnen JH, Vermorken JB. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007; 64: 622-33
- 372 Hoebbers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, **Schellens JH**, Stalpers LJ, Bartelink H, Begg AC. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemotherapy: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol 2008; 61: 1075-81
- 373 Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, **Schellens JH**, Huitema AD. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 2008; 83: 829-39
- 374 Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, **Schellens JH**. Application of PET/CT in the development of novel anticancer drugs. Oncologist 2008; 13: 25-38
- 375 Veltkamp SA, Beijnen JH, **Schellens JH**. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008; 13: 261-76
- 376 Gast MC, Engwegen JY, **Schellens JH**, Beijnen JH. Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. BMC Med Genomics 2008; 1: 4
- 377 Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, **Schellens JH**, Beijnen JH. Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin(R) given intravesically. Rapid Commun Mass Spectrom 2008; 22: 462-70
- 378 Brouwers EE, Tibben M, Rosing H, **Schellens JH**, Beijnen JH. The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. Mass Spectrom Rev 2008; 27: 67-100
- 379 Damen CW, Rosing H, **Schellens JH**, Beijnen JH. Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. J Pharm Biomed Anal 2008; 46: 449-55
- 380 Harmsen S, Koster A, Beijnen JH, **Schellens JH**, Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor mediated CYP3A4 induction. Drug Metab Dispos 2008; 36: 1166-71
- 381 Appels NMGM, Bolijn MJ, Chan K, Stephens TC, Hochtin-Boes G, Middleton M, Beijnen JH, de Bono JS, Harris AL, **Schellens JHM**. Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br J Cancer 2008; 98: 1951-58
- 382 Vainchtein LD, Rosing H, **Schellens JHM**, Beijnen JH. Ultrasensitive bioanalytical assays for cytotoxic drugs: focus on locally administered anti-cancer agents. The Open Analytical Chemistry Journal 2008; 2: 10-39
- 383 Zandvliet AS, **Schellens JHM**, Dittrich C, Wanders J, Beijnen JH, Huitema AD. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 2008; 66: 485-97
- 384 Damen CWN, Rosing H, Tibben MM, van Maanen MJ, Lagas JS, Schinkel AH, **Schellens JHM**, Beijnen JH. A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Chromatogr B 2008; 868: 102-09
- 385 Marchetti S, de Vries NA, Buckle T, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, **Schellens JHM**. Impact of the ABC-drug transporters ABCB1, ABCG2 and ABCC2 on erlotinib disposition (Tarceva[®]) in *in vitro* and *in vivo* pharmacokinetic studies employing employing Bcrp1-/-/Mdr1a/1b-/- (triple knockout) and wild-type mice. Mol Cancer Ther 2008; 7: 2280-87
- 386 Engwegen JYMN, Depla ACTM, Cats A, Smits ME, **Schellens JHM**, Beijnen JH. Detection of colorectal

cancer by serum and tissue protein profiling: a prospective study in a population at risk. *Biomarker Insights* 2008; 3: 375-85

- 387 Engwegen JYMN, Alberts M, Knol JC, Jimenez CR, Depla ACTM, Tuynman H, van Heukelem HA, Snel P, Smits ME, Cats A, **Schellens JHM**, Beijnen JH. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. *Proteomics Clin Appl* 2008; 2: 936-45
- 388 Veltkamp SA, Pluim D, van Tellingen O, Bijnen, **Schellens JHM**. Extensive metabolism and liver accumulation of gemcitabine following multiple oral and intravenous administration in mice. *Drug Met Disp* 2008; 36: 1606-15
- 389 Engwegen JYMN, Haanen JBAG, Voest EE, **Schellens JHM**, Beijnen JH. Biomarker discovery by protein profiling in kidney cancer: the current state of the art. *Kidney Cancer Journal* 2008
- 390 Derijks-Engwegen JYMN, Cats A, Smits ME, **Schellens JHM**, Beijnen JH. Improving colorectal cancer management: the proteomics potential. *Biomarker Med* 2008; 2: 253-89
- 391 Van den Broek I, Sparidans RW, **Schellens JHM**, Beijnen JH. The quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. *J Chromatography B* 2008; 872: 1-22
- 392 Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloekers-Rhoades S, Andre VAM, Beijnen JH, Slapak CA, **Schellens JHM**. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. *Clin Cancer Res* 2008; 14: 3477-86
- 393 Huijbers EJM, Baars JW, Schutte PFE, **Schellens JHM**, Beijnen JH. Propofol extravasation in a breast cancer patient. *J Oncol Pharm Practise* 2008; 14: 195-98
- 394 **Schellens JHM**, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, de Boer A, van Bortel LM. The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist-clinical pharmacologists. *Br J Clin Pharmacol* 2008; 66: 146-47
- 395 Brouwers EE, Huitema AD, **Schellens JHM**, Beijnen JH. The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. *Anticancer Drugs* 2008; 19: 621-30
- 396 Siegel-Lakhai WS, Zandvliet AS, Huitema AD, Tibben MM, Milano G, Girre V, Diéras V, King A, Richmond E, Wanders J, Beijnen JH, **Schellens JHM**. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. *Br J Cancer* 2008; 98: 1320-26
- 397 Meijerman I, Beijnen JH, **Schellens JHM**. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. *Cancer Treat Rev* 2008; 34: 505-20
- 398 Brouwers EE, Tibben MM, Pluim D, Rosing H, Boot H, Cats A, **Schellens JHM**, Beijnen JH. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. *Anal Bioanal Chem* 2008; 391: 577-85
- 399 Sparidans RW, Lagas JS, Schinkel AH, **Schellens JHM**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. *J Chromatogr B* 2008; 872: 77-82
- 400 Veltkamp SA, Pluim D, Eindhoven v MAJ, Bolijn MJ, Ong FHG, Govindarajan R, Unadkat JD, Beijnen JH, **Schellens JHM**. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. *Mol Cancer Ther* 2008; 7: 2415-25
- 401 Zandvliet AS, **Schellens JHM**, Beijnen JH, Huitema AD. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. *Clin Pharmacokinet* 2008; 47: 487-513
- 402 van den Broek I, Sparidans RW, **Schellens JHM**, Beijnen JH. Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. *Rapid Commun Mass Spectrom* 2008; 22: 2915-28
- 403 Brouwers EE, Huitema AD, Beijnen JH, **Schellens JHM**. Long-term platinum retention after treatment

with cisplatin and oxaliplatin. *BMC Clin Pharmacol* 2008; 8: 7

- 404 Deenen MJ, Beijnen JH, **Schellens JHM**. Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen? *J Clin Oncol* 2008; 26: 4997-98
- 405 Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, Heuvel van den IJ, Beijnen JH, Voest EE, **Schellens JHM**. Clinical and pharmacologic study of the novel prodrug delimitotecan (MEN 4901/T-0128) in patients with solid tumors. *Clin Cancer Res* 2008; 14: 7535-44
- 406 Gast MC, van Tinteren H, Bontenbal M, van Hoesel RQ, Nooij MA, Rodenhuis S, Span PN, Tjan-Heijnen VC, de Vries EG, Harris N, Twisk JW, **Schellens JH**, Beijnen JH. Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. *BMC Cancer* 2008; 8: 389
- 407 Smit EF, Burgers JA, Biesma B, Smit HJM, Eppinga P, Dingemans AC, Joerger M, **Schellens JHM**, Vincent A, van Zandwijk N, Groen HJM. A randomized phase III and pharmacogenetic study of pemetrexed compared to pemetrexed-carboplatin in pretreated patients with advanced NSCLC. *Journal of Clinical Oncology* 2009; 27: 2038-45
- 408 Brouwers EE, Söhne M, Kuipers S, van Gorp EC, **Schellens JH**, Koks CH, Beijnen JH, Huitema AD. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. *Clin Drug Investig* 2009; 29: 59-63
- 409 Gast MC, **Schellens JH**, Beijnen JH. Clinical proteomics in breast cancer: a review. *Breast Cancer Res Treat* 2009; 116: 17-29
- 410 Oostendorp RL, Beijnen JH, **Schellens JHM**. The biological and clinical role of drug transporters at the intestinal barrier. *Cancer Treat Rev* 2009; 35: 137-47
- 411 **Schellens JHM**, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, de Boer A, van Bortel LM. The Dutch vision of Clinical Pharmacology. *Clin Pharmacol Ther* 2009; 4: 366-68
- 412 Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, **Schellens JHM**. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. *Invest New Drugs* 2009; 27: 31-40
- 413 Harmsen S, Meijerman I, Beijnen JH, **Schellens JHM**. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. *Cancer Chemother Pharmacol* 2009; 64: 35-43
- 414 Ekhart C, Rodenhuis S, **Schellens JHM**, Beijnen JH, Huitema A. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? *Cancer Chemother Pharmacol* 2009; 64: 115-22
- 415 Keizer RJ, Zamacona MK, Jansen M, Critchley D, Wanders J, Beijnen JH, **Schellens JHM**, Huitema AD. Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. *Invest New Drugs* 2009; 27: 140-52
- 416 **Schellens JH**, Beijnen JH. Novel clinical trial designs for innovative therapies. *Clin Pharmacol Ther* 2009; 85: 212-16
- 417 Sparidans RW, Vlaming ML, Lagas JS, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877: 269-76
- 418 Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, **Schellens JH**. OATP1B1 mediates transport of gimatecan and BNP1350 and can be inhibited by several classical ABCB1 and/or ABCG2 inhibitors. *Drug Metab Dispos* 2009; 37: 917-23
- 419 Beumer JH, Lopez-Lazaro L, **Schellens JH**, Beijnen JH, van Tellingen O. Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelistrade mark, ET-743). *Curr Clin Pharmacol* 2009; 4: 38-42
- 420 Zandvliet AS, Karlsson MO, **Schellens JH**, Copalu W, Beijnen JH, Huitema AD. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. *Invest New Drugs* 2009;

- 421 Zandvliet AS, **Schellens JH**, Copalu W, Beijnen JH, Huitema AD. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. *J Pharmacokinet Pharmacodyn* 2009; 36: 39-62
- 422 Damen CW, Israëls T, Caron HN, **Schellens JH**, Rosing H, Beijnen JH. Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high performance liquid chromatography coupled with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2009; 23: 763-74
- 423 **Schellens JH**. Phase 0 (zero) clinical trials: More than zero benefit? *Eur J Cancer* 2009; 45: 728-29
- 424 Jansen RS, Rosing H, **Schellens JH**, Beijnen JH. Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: Development of a liquid chromatography-tandem mass spectrometry method. *J Chromatogr A* 2009; 1216: 3168-74
- 425 Beumer JH, Franke NE, Tolboom R, Buckle T, Rosing H, Lopez-Lazaro L, **Schellens JH**, Beijnen JH, van Tellingen O. Disposition and toxicity of trabectedin (ET-743) in wild-type and *mdr1* gene (P-gp) knock-out mice. *Invest New Drugs* 2009; 28: 145-55
- 426 Damen CW, Rosing H, **Schellens JH**, Beijnen JH. Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D. *Anal Bioanal Chem* 2009; 394: 1171-82
- 427 Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, **Schellens JH**. Persistent neuropathy after treatment with cisplatin and oxaliplatin. *Acta Oncol* 2009; 48: 832-41
- 428 Damen CW, Lagas JS, Rosing H, **Schellens JH**, Beijnen JH. The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry. *Biomed. Chromatogr* 2009; 23: 1316-25
- 429 Damen CW, Derissen EJ, **Schellens JH**, Rosing H, Beijnen JH. The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum. *J Pharm Biomed Anal* 2009; 50: 861-66
- 430 Damen CW, de Groot ER, Heij M, Boss DS, **Schellens JH**, Rosing H, Beijnen JH, Aarden LA. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. *Anal Biochem* 2009; 391: 114-20
- 431 Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, **Schellens JH**, Beijnen JH. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). *Clin Chem Lab Med* 2009; 47: 694-705
- 432 Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, **Schellens JH**. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. *Invest New Drugs* 2010; 28: 163-70
- 433 Damen CW, Rosing H, **Schellens JH**, Beijnen JH. High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature. *Biomed Chromatogr* 2009; 24: 83-90
- 434 Hendriks JJ, Beijnen JH, **Schellens JH**. Methylnaltrexone. *Oncologist* 2009; 14:679-82
- 435 Teunissen SF, Rosing H, Koornstra RH, Linn SC, **Schellens JH**, Schinkel AH, Beijnen JH. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877: 2519-29
- 436 Engwegen JY, Mehra N, Haanen JB, **Schellens JH**, Voest EE, Beijnen JH. Identification of two new serum protein profiles for renal cell carcinoma. *Oncol Rep* 2009; 22: 401-08

- 437 Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, **Schellens JH**, de Bono JS. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009; 361: 123-34
- 438 Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, **Schellens JH**. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. *Clin Cancer Res* 2009; 15: 4475-83
- 439 Damen CW, Speijer H, Hermens WT, **Schellens JH**, Rosing H, Beijnen JH. The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry. *Anal Biochem* 2009; 393: 73-79
- 440 Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, **Schellens JH**, Beijnen JH. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. *Oncol Rep* 2009; 22: 205-13
- 441 Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, **Schellens JH**. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. *Clin Cancer Res* 2009; 15: 4228-33
- 442 Pluim D, Beijnen JH, **Schellens JH**, van Tellingen O. Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877: 3549-55
- 443 Damen CW, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, **Schellens JH**, Rosing H, Beijnen JH. Electrospray Ionization Quadrupole Ion-Mobility Time-of-Flight Mass Spectrometry as a Tool to Distinguish the Lot-to-Lot Heterogeneity in N-Glycosylation Profile of the Therapeutic Monoclonal Antibody Trastuzumab. *J Am Soc Mass Spectrom* 2009; 20: 2021-33
- 444 Damen CW, **Schellens JH**, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. *Hum Antibodies* 2009; 18: 47-73
- 445 Koolen SL, Huitema AD, Jansen RS, van Voorthuizen T, Beijnen JH, Smit WM, **Schellens JH**. Pharmacokinetics of Gemcitabine and Metabolites in a Patient with Double-Sided Nephrectomy: A Case Report and Review of the Literature. *Oncologist* 2009; 14: 944-48
- 446 Jansen RS, Rosing H, **Schellens JH**, Beijnen JH. Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2009; 23: 3040-50
- 447 Jansen RS, Rosing H, **Schellens JH**, Beijnen JH. Protein versus DNA as a marker for peripheral blood mononuclear cell counting. *Anal Bioanal Chem* 2009; 395: 863-67
- 448 Boss DS, Beijnen JH, **Schellens JH**. Clinical experience with aurora kinase inhibitors: a review. *Oncologist* 2009; 14: 780-93
- 449 Vainchtein LD, Rosing H, **Schellens JH**, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. *Biomed Chromatogr* 2009; 24: 374-86
- 450 Koolen SL, Beijnen JH, **Schellens JH**. Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel. *Clin Pharmacol Ther.* 2009; 87: 126-29
- 451 Sparidans RW, Iusuf D, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877: 4090-96
- 452 Langenberg MH, van Herpen CM, De Bono J, **Schellens JH**, Unger C, Hoekman K, Blum HE, Fiedler W, Dreves J, Le Maulf F, Fielding A, Robertson J, Voest EE. Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid

Tumors. *J Clin Oncol* 2009; 27: 6152-59

- 453 Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, **Schellens JH**, Shapiro GI. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. *Ann Oncol* 2009; 21: 884-94
- 454 Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, **Schellens JH**, Beijnen JH. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. *Int J Biol Markers* 2009; 24: 130-41
- 455 Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, **Schellens JH**, Beijnen JH. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877: 3625-30
- 456 Jansen RS, Rosing H, **Schellens JH**, Beijnen JH. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? *Fundam Clin Pharmacol* 2010; 25: 172-85
- 457 Joerger M, Huitema AD, Krähenbühl S, **Schellens JH**, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri AJ. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic- pharmacodynamic analysis from the IELSG no. 20 trial. *Br J Cancer*. 2010; 102: 673-77
- 458 Jansen RS, Rosing H, Kromdijk W, ter Heine R, **Schellens JH**, Beijnen JH. Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2010; 878: 621-27
- 459 van den Broek I, Sparidans RW, **Schellens JH**, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2010; 878: 590-602
- 460 Cömezoğlu SN, Ly VT, Zhang D, Humphreys WG, Bonacorsi SJ, Everett DW, Cohen MB, Gan J, Beumer JH, Beijnen JH, **Schellens JHM**, Lappin G. Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). *Drug Metab Pharmacokinet*. 2009; 24: 511-22
- 461 Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, **Schellens JH**. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. *Cancer Chemother Pharmacol*. 2009; 66: 765-71
- 462 Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, **Schellens JH**, Beijnen JH, Voest EE. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. *Ann Oncol*. 2009; 21: 1472-81
- 463 Helgason HH, Engwegen JYMN, Zapatka M, Vincent A, Cats A, Boot H, Beijnen JH, **Schellens JHM**. Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. *Oncology reports* 2010; 24: 57-64
- 464 Helgason HH, Engwegen JYMN, Zapatka M, Cats A, Boot H, Beijnen JH, **Schellens JHM**. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. *Oncology letters* 2010; 1: 327-33
- 465 Keizer RJ, van Benten M, Beijnen JH, **Schellens JHM**, Huitema ADR. Piraña and Pcluster: A modeling environment and cluster infrastructure for NONMEM. *Comput Methods Programs Biomed* 2010; 101: 72-79
- 466 Jansen RS, Rosing H, **Schellens JHM**, Beijnen JH. Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. *Mass Spectrom Rev* 2010; 30: 321-43

- 467 Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, **Schellens JH**, Karlsson MO, Huitema AD. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. *J Pharmacokinet Pharmacodyn* 2010; 37: 347-63
- 468 Goey AK, **Schellens JH**, Beijnen JH, Huitema AD. [Dexrazoxane in anthracycline induced cardio-toxicity and extravasation]. *Ned Tijdschr Geneesk* 2010; 154 : A1155
- 469 Keizer RJ, Huitema AD, **Schellens JH**, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. *Clin Pharmacokinet* 2010; 49: 493-507
- 470 Buikhuisen WA, Burgers JA, Vincent AD, **Schellens JH**, Beijnen JH, Smit EF, Joerger M. Pemetrexed Pathway-Associated Germline Polymorphisms: A Useful Tool for Treatment Individualization? *J Clin Oncol* 2010; 28: 482-83
- 471 Sparidans RW, van Velsen SG, de Roos MP, **Schellens JH**, Bruijnzeel-Koomen CA, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010; 878: 2150-54
- 472 Koolen SL, Oostendorp RL, Beijnen JH, **Schellens JH**, Huitema AD. Population pharmaco-kinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. *Br J Clin Pharmacol* 2010; 69: 465-74
- 473 van Winden AW, van den Broek I, Gast MC, Engwegen JY, Sparidans RW, van Dulken EJ, Depla AC, Cats A, **Schellens JH**, Peeters PH, Beijnen JH, van Gils CH. Serum degradome markers for the detection of breast cancer. *J Proteome Res* 2010; 9: 3781-88
- 474 van den Broek I, Sparidans RW, **Schellens JH**, Beijnen JH. Sensitive liquid chromatography/ tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples. *Rapid Commun Mass Spectrom* 2010; 24: 1842-50
- 475 Beijnen JH, **Schellens JH**. Selected New Developments in Oncology. *Curr Clin Pharmacol* 2010; 5: 140
- 476 Beijnen JH, **Schellens JH**. Personalized Medicine in Oncology: A Personal View with Myths and Facts. *Curr Clin Pharmacol* 2010; 5: 141-47
- 477 Leijen S, Beijnen JH, **Schellens JH**. Abrogation of the G(2) Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents. *Curr Clin Pharmacol* 2010; 5: 186-91
- 478 Boss DS, Beijnen JH, **Schellens JH**. Inducing Synthetic Lethality using PARP Inhibitors. *Curr Clin Pharmacol* 2010; 5: 192-95
- 479 Jansen RS, Rosing H, **Schellens JH**, Beijnen JH. Facile small scale synthesis of nucleoside 5'-phosphate mixtures. *Nucleosides Nucleotides Nucleic Acids* 2010; 29:14-26
- 480 Oostendorp RL, Buckle T, Lambert G, Garrigue JS, Beijnen JH, **Schellens JH**, van Tellingen O. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. *Invest New Drugs* 2010; 29: 768–776
- 481 van den Broek I, Sparidans RW, **Schellens JH**, Beijnen JH. Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010; 878: 1085-92
- 482 Appels NM, Bolijn MJ, van Eijndhoven MA, Stephens TC, Beijnen JH, **Schellens JH**. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. *Cancer Chemother Pharmacol* 2010; 67: 137-45
- 483 Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, **Schellens JH**. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. *Ann Oncol* 2010; 22: 431-37
- 484 Klümpen HJ, Samer CF, Mathijssen RH, **Schellens JH**, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. *Cancer Treat Rev* 2010; 37: 251-60

- 485 Sparidans RW, Iusuf D, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010; 878: 2751-59
- 486 Teunissen SF, Vlaming ML, Rosing H, **Schellens JH**, Schinkel AH, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010; 878: 2353-62
- 487 Kazazi-Hyseni F, Beijnen JH, **Schellens JH**. Bevacizumab. *Oncologist* 2010; 15: 819-25
- 488 van der Bol JM, Visser TJ, Loos WJ, de Jong FA, Wiemer EA, van Aken MO, Planting AS, **Schellens JH**, Verweij J, Mathijssen RH. Effects of methimazole on the elimination of irinotecan. *Cancer Chemother Pharmacol* 2010; 67: 231-36
- 489 Keizer RJ, van Benten M, Beijnen JH, **Schellens JH**, Huitema AD. Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM. *Comput Methods Programs Biomed* 2010; 101: 72-79
- 490 Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, **Schellens JH**, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. *J Clin Oncol* 2010; 28: 2505-11
- 491 Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, **Schellens JH**, de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol* 2010; 28: 2512-19
- 492 Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, **Schellens JH**, Voest EE. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. *Clin Cancer Res* 2010; 16: 2187-97
- 493 Koolen SL, Beijnen JH, **Schellens JH**. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. *Clin Pharmacol Ther* 2010; 87: 126-29
- 494 Sparidans RW, Iusuf D, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877: 4090-96
- 495 Langenberg MH, van Herpen CM, De Bono J, **Schellens JH**, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. *J Clin Oncol* 2009; 27: 6152-59
- 496 Goey AKL, Sparidans RW, Meijerman I, Rosing H, **Schellens JHM**, Beijnen JH. A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. *J Chromatogr Analyt Technol Biomed Life Sci* 2010; 879: 41-48
- 497 de Vries NA, Buckle T, Zhao J, Beijnen JH, **Schellens JH**, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. *Invest New Drugs* 2010; 30: 443-49
- 498 Janssens T, Brouwers EE, de Vos JP, **Schellens JH**, Beijnen JH. Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry. *J Pharm Biomed Anal* 2010; 54: 395-400
- 499 Klümpen HJ, Samer CF, Mathijssen RH, **Schellens JH**, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. *Cancer Treat Rev* 2010; 37: 251-60

- 500 Klümpen HJ, Beijnen JH, Gurney H, **Schellens JHM**. Inhibitors of mTOR. *The Oncologist* 2010; 15: 1262-69
- 501 Teunissen SF, Rosing H, Schinkel AH, **Schellens JH**, Beijnen JH. Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010; 878: 3199-3216
- 502 Teunissen SF, Rosinga H, Schinkel AH, **Schellens JHM**, Beijnen JH. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review. *Analytica Chimica Acta* 2010; 683: 21–37
- 503 van den Broek I, Sparidans RW, **Schellens JHM**, Beijnen JH. Specific investigation of sample handling effects on protease activities and absolute serum concentrations of various putative peptidome cancer biomarkers. *Clin Proteom* 2010; 6: 115-27
- 504 van den Broek I, Sparidans RW, van Winden AWJ, Gast MW, van Dulken EJ, **Schellens JHM**, Beijnen JH. The absolute quantification of eight inter- α -trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. *Proteomics Clin Appl* 2010; 4: 931-39
- 505 Deenen MJ, Terpstra WE, Cats A, Boot H, **Schellens JH**. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-Fluorouracil or capecitabine. *Ann Intern Med* 2010; 153: 767-68
- 506 van den Broek I, Sparidans RW, Engwegen JY, Cats A, Depla AC, **Schellens JH**, Beijnen JH. Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer. *Cancer Biomark* 2010; 7:109-15
- 507 Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TRJ, **Schellens JHM**. Serum β -HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. *Tumori* 2011; 109-14
- 508 Dubbelman AC, Rosing H, Thijssen B, Lucas L, Copalu W, Wanders J, **Schellens JH**, Beijnen JH. Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. *J Chromatogr B Analyt Technol Biomed Life Sci* 2011; 879: 1149-55
- 509 Janssens T, Brouwers EE, de Vos JP, **Schellens JH**, Beijnen JH. Determination of platinum originating from Carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry. *J Anal Toxicol* 2011; 35:153-61
- 510 Teunissen SF, Rosing H, Seoane MD, Brunsveld L, **Schellens JH**, Schinkel AH, Beijnen JH. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. *J Pharm Biomed Anal* 2011; 55: 518-26
- 511 Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, **Schellens JH**, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. *Invest New Drugs* 2011; 29: 984-95
- 512 Keizer RJ, Funahashi Y, Semba T, Wanders J, Beijnen JH, **Schellens JH**, Huitema AD. Evaluation of α 2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. *AAPS J* 2011; 13: 230-39
- 513 Langenberg MH, Witteveen PO, Roodhart J, Lolkema MP, Verheul HM, Mergui-Roelvink M, Brendel E, Krätzschar J, Loembé B, Nol-Boekel A, Christensen O, **Schellens JH**, Voest EE. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. *Ann Oncol* 2011; 22: 2508-15
- 514 Keizer RJ, **Schellens JH**, Beijnen JH, Huitema AD. Pharmacodynamic biomarkers in model-based drug development in oncology. *Curr Clin Pharmacol* 2011; 6: 30-40
- 515 Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, **Schellens JH**. Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. *Clin Cancer Res* 2011; 17: 1131-39

- 516 van Hasselt JGC, Boekhout AH, Beijnen JH, **Schellens JHM**, Huitema ADR. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. *Clin Pharmacol Ther* 2011; 90: 126-32
- 517 Keizer RJ, Zandvliet AS, Beijnen JH, **Schellens JHM**, Huitema ADR. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). *Invest New Drugs* 2011; 30: 1519-30
- 518 Sparidans RW, Martens I, Valkenburg-van Iersel LBJ, den Hartigh J, **Schellens JHM**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. *J Chromatogr B* 2011; 1851-56
- 519 Hendriks JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, **Schellens JH**, Beijnen JH. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2011; 879: 2984-90
- 520 Gast MC, Zapatka M, van Tinteren H, Bontenbal M, Span PN, Tjan-Heijnen VC, Knol JC, Jimenez CR, **Schellens JH**, Beijnen JH. Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. *J Cancer Res Clin Oncol* 2011; 137: 1773-83
- 521 Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, **Schellens JH**. Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial. *J Clin Oncol* 2011; 29: 3862-68
- 522 Moes JJ, Koolen SL, Huitema AD, **Schellens JH**, Beijnen JH, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). *Int J Pharm* 2011; 420: 244-50
- 523 Deenen MJ, **Schellens JH**, Cats A. SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Response. *Clin Cancer Res* 2011; 17: 5835-36
- 524 Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, Tonda M, **Schellens JH**, Beijnen JH, Zamboni WC. Allometric scaling of pegylated liposomal anticancer drugs. *J Pharmacokinet Pharmacodyn* 2011; 38: 653-69
- 525 Joerger M, Ferreri AJ, Krähenbühl S, **Schellens JH**, Cerny T, Zucca E, Huitema AD. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. *Br J Clin Pharmacol* 2011; 73: 240-47
- 526 Devriese LA, Bosma AJ, van de Heuvel MM, Heemsbergen W, Voest EE, **Schellens JH**. Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis. *Lung Cancer* 2011; 75: 242-47
- 527 Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, **Schellens JH**, Wilmink JW. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. *Invest New Drugs* 2011; 30: 1557-65
- 528 Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, **Schellens JH**. Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors. *Clin Cancer Res* 2011; 17: 6071-82
- 529 Deenen MJ, Cats A, Beijnen JH, **Schellens JH**. Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. *Oncologist* 2011; 16: 1006-20
- 530 Deenen MJ, Cats A, Beijnen JH, **Schellens JH**. Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism. *Oncologist* 2011; 16: 992-1005
- 531 Deenen MJ, Cats A, Beijnen JH, **Schellens JH**. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. *Oncologist* 2011; 16: 820-34
- 532 Boekhout AH, Beijnen JH, **Schellens JH**. Trastuzumab. *Oncologist* 2011; 16: 800-10

- 533 Deenen MJ, Cats A, Beijnen JH, **Schellens JH**. Part 1: background, methodology, and clinical adoption of pharmacogenetics. *Oncologist* 2011; 16: 811-19
- 534 Devriese LA, Voest EE, Beijnen JH, **Schellens JH**. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. *Cancer Treat Rev* 2011; 37: 579-89
- 535 Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, **Schellens JH**. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. *Cancer Chemother Pharmacol* 2011; 69: 25-33
- 536 Molloy TJ, Devriese LA, Helgason HH, Bosma AJ, Hauptmann M, Voest EE, **Schellens JH**, van't Veer LJ. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. *Br J Cancer* 2011; 104: 1913-9
- 537 Teunissen SF, Jager NG, Rosing H, Schinkel AH, **Schellens JH**, Beijnen JH. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2011; 879: 1677-85
- 538 Trotta F, Leufkens HG, **Schellens JH**, Laing R, Tafuri G. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. *J Clin Oncol* 2011; 29: 2266-72
- 539 Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, **Schellens JH**. Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy *Lung Cancer* 2011; 74: 310-17
- 540 Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, **Schellens JH**, Huitema AD. From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies. *J Clin Pharmacol* 2011; 52: 370-80
- 541 Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, **Schellens JH**, Cats A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. *Clin Cancer Res* 2011; 17: 3455-68
- 542 Leijen S, Soetekouw PM, Jeffry Evans TR, Nicolson M, **Schellens JH**, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2011; 68: 1619-28
- 543 Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, **Schellens JH**, Beijnen JH. Mass Balance Study of ¹⁴C-eribulin in Patients with Advanced Solid Tumours. *Drug Metab Dispos* 2011; 40: 313-21
- 544 Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, **Schellens JH**. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: A prospective clinical study. *Cancer* 2011; 118: 2466-75
- 545 Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, **Schellens JH**, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. *J Anal Toxicol* 2011; 35: 558-65
- 546 Nieto M, Borregaard J, Ersbøll J, Ten Bosch GJ, van Zwieten-Boot B, Abadie E, **Schellens JH**, Pignatti F. The European medicines agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the committee for medicinal products for human use. *Clin Cancer Res* 2011; 17: 6608-14
- 547 Bergamo A, Gaiddon C, **Schellens JH**, Beijnen JH, Sava G. Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates. *J Inorg Biochem* 2011;

- 548 Dubbelman AC, Rosing H, **Schellens JH**, Beijnen JH. Bioanalytical aspects of clinical mass balance studies in oncology. *Bioanalysis* 2011; 3: 2637-55
- 549 Jansen RS, Rosing H, Wijermans PW, Keizer RJ, **Schellens JH**, Beijnen JH. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. *Cancer Chemother Pharmacol* 2012; 69: 1457-66
- 550 Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, **Schellens JH**, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. *J Clin Oncol* 2012; 30: 996-1004
- 551 Dubbelman AC, Rosing H, Thijssen B, Gebretensae A, Lucas L, Chen H, Shumaker R, **Schellens JH**, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012; 887-888: 25-34
- 552 Keizer RJ, Gupta A, Shumaker R, Beijnen JH, **Schellens JH**, Huitema AD. Model-based treatment optimisation of a novel VEGFR-inhibitor. *Br J Clin Pharmacol* 2012; 74: 315-26
- 553 Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, **Schellens JH**, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. *Eur Urol* 2012; 62: 685-95
- 554 Manson ML, Derissen EJ, Wijermans PW, **Schellens JH**, Beijnen JH. [Demethylating medication in myelodysplastic syndrome]. *Ned Tijdschr Geneesk* 2012; 156: A3167
- 555 Frederix GW, Severens JL, Hövels AM, Raaijmakers JA, **Schellens JH**. Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes. *Value Health* 2012; 15: 94-105
- 556 Sparidans RW, Durmus S, Schinkel AH, **Schellens JHM**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012; 889-890:144-47
- 557 Devriese LA, Witteveen PO, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema ADR, Voest EE, **Schellens JHM**. Pharmacokinetics of eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin. *Br J Clin Pharmacol* 2012; 75: 507-15
- 558 Pluim D, Devriese L, Beijnen JH, **Schellens JHM**. Validation of a multi-parameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. *Cytometry Part A* 2012; 81: 664-71
- 559 Sparidans RW, Durmus S, Xu N, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N(+)-glucuronide in plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012; 895-896:169-73
- 560 Sparidans RW, Durmus S, Xu N, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012; 895-896: 174-77
- 561 van Hasselt JCG, van den Heuvel MM, **Schellens JHM**, Beijnen JH, Brandsma D, Huitema ADR. Severe cannabinoid intoxication in a patient with non-small-cell lung cancer. *J Palliat Care* 2012; 28, 60-61
- 562 Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, **Schellens JH**, Evans TR. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. *Br J Cancer* 2012; 106: 1598-604
- 563 van Geel RM, Beijnen JH, **Schellens JH**. Clinical pharmacology: concise drug review: pazopanib and axitinib. *Oncologist* 2012; 17: 1081-89

- 564 Keizer RJ, Zandvliet AS, Beijnen JH, **Schellens JH**, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. *AAPS J*. 2012; 14: 601-11
- 565 Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, **Schellens JH**. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. *Invest New Drugs* 2012; 31: 381-89
- 566 Mooiman KD, Goey AK, Meijerman I, Beijnen JH, **Schellens JH**. Letter to the Editor Regarding "A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer" by Yaal-Hahoshen et al. (*The Oncologist* 2011;16:1197-1202). *Oncologist*. 2012; 17: 740-41
- 567 Dubbelman AC, Jansen RS, Rosing H, Darwish M, Hellriegel E, Robertson P Jr, **Schellens JH**, Beijnen JH. Metabolite Profiling of Bendamustine in Urine of Cancer Patients after Administration of [¹⁴C] Bendamustine. *Drug Metab Dispos* 2012; 40: 1297-307
- 568 Opdam FL, Guchelaar HJ, Beijnen JH, **Schellens JH**. Lapatinib for advanced or metastatic breast cancer. *Oncologist* 2012; 17: 536-42
- 569 Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P Jr, **Schellens JH**, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012; 893-894: 92-100
- 570 Jager NG, Rosing H, Linn SC, **Schellens JH**, Beijnen JH. Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. *Breast Cancer Res Treat* 2012; 133: 793-98
- 571 Goey AK, Rosing H, Meijerman I, Sparidans RW, **Schellens JH**, Beijnen JH. The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012; 902: 151-56
- 572 Leijen S, Middleton MR, Tresca P, Kraeber-Bodere F, Dieras V, Scheulen M, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Meresse Naegelen V, **Schellens JH**, Eberhardt WE. Phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumours. *Clin Cancer Res* 2012; 18: 4794-805
- 573 van Leeuwen WA, **Schellens JH**, Becker HE, de Haan L, van Westrhenen R. [The subclinical course of a paracetamol intoxication: pitfall for patient and clinician]. *Tijdschr Psychiatr* 2012; 54: 555-59
- 574 Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, **Schellens JH**, Wilmink JW. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. *Invest New Drugs* 2012; 30:1557-65
- 575 Keizer RJ, Zandvliet AS, Beijnen JH, **Schellens JH**, Huitema AD. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). *Invest New Drugs* 2012; 30: 1519-30
- 576 Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, **Schellens JH**, Beijnen JH, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly Paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. *Clin Pharmacokinet* 2012; 51: 607-17
- 577 van Hasselt JG, **Schellens JH**, Mac Gillavry MR, Beijnen JH, Huitema AD. Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab. *Pharm Res* 2012; 29: 3499-511
- 578 Sparidans RW, Tang SC, Nguyen LN, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012; 905: 150-54
- 579 Deenen MJ, Cats A, Mandigers CM, Soesan M, Terpstra WE, Beijnen JH, **Schellens JH**. Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency. *Ned*

- 580 Lankheet N, Schaake E, Rosing H, Burgers J, **Schellens J**, Beijnen J, Huitema A. Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue. *Bioanalysis*. 2012; 4: 2563-77
- 581 Hendrikx JJ, Lagas JS, Rosing H, **Schellens JH**, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. *Int J Cancer*. 2012; 132: 2439-47
- 582 Moes J, Koolen S, Huitema A, **Schellens J**, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. *Eur J Pharm Biopharm*. 2012; 83: 87-94
- 583 Milojkovic Kerklaan B, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, **Schellens JH**, Awada A. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. *Cancer Chemother Pharmacol*. 2012; 71: 53-62
- 584 Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, **Schellens JH**. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. *Cancer Chemother Pharmacol*. 2012; 70: 823-32
- 585 Dubbelman AC, Uthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, **Schellens JH**. Disposition and metabolism of (¹⁴C)-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2012; 70: 653-63
- 586 Lankheet NA, Hillebrand MJ, Rosing H, **Schellens JH**, Beijnen JH, Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. *Biomed Chromatogr*. 2012; 27: 466-76
- 587 Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, **Schellens JH**, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. *Br J Cancer*. 2012; 107: 1025-30
- 588 Sparidans RW, Ahmed TT, Muilwijk EW, Welzen ME, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2012; 905: 137-40
- 589 Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, **Schellens JH**, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. *Br J Cancer*. 2012; 107: 1025-30
- 590 Nijenhuis CM, Haanen JB, **Schellens JH**, Beijnen JH. Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? *Cancer Treat Rev*. 2013; 39: 305-12
- 591 Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, **Schellens JH**, Hendlisz A. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. *Invest New Drugs* 2013; 31: 959-66
- 592 Milojkovic Kerklaan B, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, **Schellens JH**, Awada A. Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. *Cancer Chemother Pharmacol* 2013; 71: 553
- 593 Deenen MJ, Cats A, Beijnen JH, **Schellens JH**. Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. *Ther Adv Med Oncol* 2013; 5: 91-92
- 594 Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, Robertson P Jr, Beijnen JH,

Schellens JH. Pharmacokinetics and Excretion of (14)C-Bendamustine in Patients with Relapsed or Refractory Malignancy. *Drugs R D* 2013; 13: 17-28

- 595 Pluim D, Jacobs BA, Krähenbühl MD, Ruijter AE, Beijnen JH, **Schellens JH.** Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. *Anal Bioanal Chem* 2013; 405: 2391-95
- 596 Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, **Schellens JH.** Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. *Invest New Drugs* 2013; 31: 1125-35
- 597 Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörgen M, **Schellens JH,** Hempel G. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. *Cancer Chemother Pharmacol* 2013; 71: 749-63
- 598 Pluim D, Schilders KA, Jacobs BA, Vaartjes D, Beijnen JH, **Schellens JH.** Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. *Anal Bioanal Chem* 2013; 405: 2495-503
- 599 Harmsen S, Meijerman I, Maas-Bakker RF, Beijnen JH, **Schellens JH.** PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. *Eur J Pharm Sci* 2013 ; 48: 644-49
- 600 Deenen MJ, Rosing H, Hillebrand MJ, **Schellens JH,** Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2013; 913-914: 30-40
- 601 Meulenaar J, Beijnen JH, **Schellens JH,** Nuijen B. Slow dissolution behaviour of amorphous capecitabine. *Int J Pharm* 2013; 441: 213-17
- 602 van Hasselt J, van Eijkelenburg N, Beijnen J, **Schellens J,** Huitema A. Optimizing drug development of anti-cancer drugs in children using modelling and simulation. *Br J Clin Pharmacol* 2013; 76: 30-47
- 603 Goey AK, Mooiman KD, Beijnen JH, **Schellens JH,** Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. *Cancer Treat Rev* 2013; 39: 773-83
- 604 Stuurman FE, Nuijen B, Beijnen JH, **Schellens JH.** Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. *Clin Pharmacokinet* 2013; 52: 399-414
- 605 van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, **Schellens JH.** Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. *Cancer Treat Rev* 2013; 39: 664-72
- 606 Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, **Schellens JH,** Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. *Clin Cancer Res* 2013; 19: 2084-95
- 607 da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, **Schellens JH,** Giuliani R, Pignatti F. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. *Eur J Cancer* 2013; 49: 1654-61
- 608 Lankheet NA, Steeghs N, Rosing H, **Schellens JH,** Beijnen JH, Huitema AD. Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. *Ther Drug Monit* 2013; 35: 168-76
- 609 Frederix GW, van Hasselt JG, Severens JL, Hövels AM, Huitema AD, Raaijmakers JA, **Schellens JH.** Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R. *Med Decis Making* 2013; 33: 780-92
- 610 Deenen MJ, Dewit L, Boot H, Beijnen JH, **Schellens JH,** Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal

carcinoma: a phase 1 study. *Int J Radiat Oncol Biol Phys* 2013; 85: e201-07

- 611 Sparidans RW, Durmus S, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2013; 925: 124-28
- 612 Frederix GW, Quadri N, Hövels AM, van de Wetering FT, Tamminga H, **Schellens JH**, Lloyd AJ. Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and Sweden. *Clin Ther* 2013; 35: e1-7
- 613 Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, **Schellens JH**, Beijnen JH. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2013; 925: 117-23
- 614 van Hasselt JG, van Eijkelenburg NK, Huitema AD, **Schellens JH**, Schouten-van Meeteren AY. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. *Antimicrob Agents Chemother* 2013; 57: 2878-81
- 615 van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, **Schellens JH**, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate associated neutropenia. *Br J Clin Pharmacol* 2013; 76: 412-24
- 616 Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Raaijmakers JA, **Schellens JH**. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer. *Breast Cancer Res Treat* 2013; 139: 489-95
- 617 Dorlo TP, Jager NG, Beijnen JH, **Schellens JH**. Concomitant use of proton pump inhibitors and systemic corticosteroids. *Ned Tijdschr Geneeskd* 2013; 157: A5540
- 618 Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, **Schellens JH**. Taxanes: Old drugs, new oral formulations. *Eur J Pharmacol* 2013; 717: 1-3
- 619 Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, **Schellens JH**. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. *Gynecol Oncol* 2013; 130: 511-17
- 620 Derissen EJ, Beijnen JH, **Schellens JH**. Concise drug review: azacitidine and decitabine. *Oncologist* 2013; 18: 619-24
- 621 Mooiman KD, Maas-Bakker RF, Rosing H, Beijnen JH, **Schellens JH**, Meijerman I. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. *Biomed Chromatogr* 2013; 27: 1107-16
- 622 Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, **Schellens JH**, Meijerman I. Milk thistle's active components ilybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. *Drug Metab Dispos* 2013; 41: 1494-504
- 623 Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, Marchetti S, Beijnen JH, **Schellens JH**. The effect of *Echinacea purpurea* on the pharmacokinetics of docetaxel. *Br J Clin Pharmacol* 2013; 76: 467-74
- 624 Janssens T, Brouwers EE, de Vos JP, de Vries N, **Schellens JH**, Beijnen JH. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs. *Vet Comp Oncol* 2013; 10.1111/vco.12025
- 625 Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, Voest EE, **Schellens JH**. A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. *J Clin Pharmacol* 2013; 53: 878-83
- 626 Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, **Schellens JH**, Meijerman I. Effect of chinese herbs

on CYP3A4 activity and expression in vitro. *J Ethnopharmacol* 2013; 149: 543-49

- 627 Goey AK, Meijerman I, Beijnen JH, **Schellens JH**. The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. *Eur J Clin Pharmacol* 2013; 69: 1883-90
- 628 Luethi D, Durmus S, Schinkel AH, **Schellens JH**, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2013; 934: 22-25
- 629 Hendriks JJ, Dubbelman AC, Rosing H, Schinkel AH, **Schellens JH**, Beijnen JH. Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2013; 27: 1925-34
- 630 Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, **Schellens JH**, Beijnen JH, Blank CU. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. *Eur J Clin Pharmacol* 2013;69: 2065-72
- 631 Hendriks JJ, Rosing H, Schinkel AH, **Schellens JH**, Beijnen JH. Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. *Biomed Chromatogr* 2013; 28: 302-10
- 632 Janssens T, Brouwers EE, de Vos JP, de Vries N, **Schellens JH**, Beijnen JH. Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry. *Vet Comp Oncol* 2013; 10.1111/vco.12025
- 633 Frederix GW, Severens JL, Hövels AM, Raaijmakers JA, **Schellens JH**. The cloudy crystal ball of cost-effectiveness studies. *Value Health* 2013; 16: 1100-02
- 634 Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, **Schellens JH**. The Effect of St John's Wort on the Pharmacokinetics of Docetaxel. *Clin Pharmacokinet* 2013; 53: 103-10
- 635 Dolman ME, den Hartog IJ, Molenaar JJ, **Schellens JH**, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. *J Pharm Biomed Anal* 2013; 88: 216-20
- 636 Nijenhuis CM, Lucas L, Rosing H, **Schellens JH**, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2013; 940: 121-25
- 637 Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F, Cerny T, **Schellens JH**, Gillessen S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. *Cancer Chemother Pharmacol* 2013; 73: 113-24
- 638 Sparidans RW, Durmus S, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. *J Pharm Biomed Anal* 2013; 88: 626-9
- 639 Nijenhuis CM, Rosing H, **Schellens JH**, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. *J Pharm Biomed Anal* 2013;88: 630-35
- 640 Helgason H, Koolen S, van Werkhoven E, Malingré M, Kruijtzter C, Huitema A, Schot M, Smit W, Beijnen J, **Schellens J**. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. *Curr Clin Pharmacol* 2013; 9: 139-47
- 641 Kloth JS, Klümpen HJ, Yu H, Eechoute K, Samer CF, Kam BL, Huitema AD, Daali Y, Zwiderman AH, Balakrishnar B, Bennink RJ, Wong M, **Schellens JH**, Mathijssen RH, Gurney H. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. *Clin Pharmacokinet* 2013; 53: 261-69
- 642 Frederix GW, van Hasselt JG, **Schellens JH**, Hövels AM, Raaijmakers JA, Huitema AD, Severens JL. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.

- 643 Lankheet NA, Knapen LM, **Schellens JH**, Beijnen JH, Steeghs N, Huitema AD. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. *Ther Drug Monit* 2013; 36: 326-34
- 644 Meulenaar J, Keizer RJ, Beijnen JH, **Schellens JH**, Huitema AD, Nuijen B. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. *J Pharm Sci* 2013; 103: 478-84
- 645 Derissen EJ, Hillebrand MJ, Rosing H, Otten HM, Laille E, **Schellens JH**, Beijnen JH. Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. *J Pharm Biomed Anal* 2013; 90: 7-14
- 646 Devriese LA, Koch KM, Mergui-Roelvink M, Matthys GM, Ma WW, Robidoux A, Stephenson JJ, Chu QS, Orford KW, Cartee L, Botbyl J, Arya N, **Schellens JH**. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. *Invest New Drugs* 2013; 32: 481-88
- 647 Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, **Schellens JH**, Linn SC, Beijnen JH. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. *BMC Cancer* 2013; 13: 612
- 648 Mooiman KD, Maas-Bakker RF, Hendriks JJ, Bank PC, Rosing H, Beijnen JH, **Schellens JH**, Meijerman I. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. *J Pharm Pharmacol* 2014; 66: 865-74
- 649 Guchelaar HJ, Gelderblom H, van der Straaten T, **Schellens JH**, Swen JJ. Pharmacogenetics in the cancer clinic: from candidate gene studies to next generation sequencing. *Clin Pharmacol Ther* 2014; 95: 383-85
- 650 Jager NG, Rosing H, **Schellens JH**, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. *Breast Cancer Res Treat* 2014; 143: 477-83
- 651 Bazargani YT, de Boer A, **Schellens JH**, Leufkens HG, Mantel-Teeuwisse AK. Selection of oncology medicines in low- and middle-income countries. *Ann Oncol* 2014; 25: 270-76
- 652 Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, **Schellens JH**, Beijnen JH, Schinkel AH. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. *Mol Pharmacol* 2014; 85: 520-30
- 653 Dolman ME, den Hartog IJ, Molenaar JJ, **Schellens JH**, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. *J Pharm Biomed Anal* 2014; 92: 144-48
- 654 Yu H, Steeghs N, Nijenhuis CM, **Schellens JH**, Beijnen JH, Huitema AD. Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets. *Clin Pharmacokinet* 2014; 53: 305-25
- 655 Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, **Schellens JH**, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D. Outcome of patients with sarcoma and other mesenchymal tumors participating in phase I trials: a subset analysis of a European Phase I database. *Ann Oncol* 2014; 25: 1222-28
- 656 Bins S, **Schellens JH**, Voest EE, Sleijfer S. Drug research in oncology; advances in the genome era. *Ned Tijdschr Geneesk* 2014; 158: A6801
- 657 Luethi D, Durmus S, Schinkel AH, **Schellens JH**, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. *Biomed Chromatogr* 2014; 28: 1366-70

- 658 de Weger VA, Beijnen JH, **Schellens JH**. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel - a review. *Anticancer Drugs* 2014; 25: 488-94
- 659 Goey AK, Beijnen JH, **Schellens JH**. Herb-drug interactions in oncology. *Clin Pharmacol Ther* 2014; 95: 354-5
- 660 van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, **Schellens JH**, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. *Biomed Res Int* 2014; 897216
- 661 van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, **Schellens JH**, Beijnen JH, Huitema AD, Amant F. Optimizing anti-cancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. *Ann Oncol* 2014; 25: 2059-65
- 662 Hendriks JJ, Lagas JS, Daling R, Hooijberg JH, **Schellens JH**, Beijnen JH, Brandjes DP, Huitema AD. Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. *Basic Clin Pharmacol Toxicol* 2014; 115: 472-75
- 663 Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, **Schellens JH**, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. *J Pharm Pharmacol* 2014; 66: 1339-46
- 664 Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, **Schellens JH**, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. *Br J Cancer* 2014; 110: 2441-49
- 665 Hendriks JJ, Lagas JS, Wagenaar E, Rosing H, **Schellens JH**, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. *Br J Cancer* 2014; 110: 2669-76
- 666 van Hasselt JG, **Schellens JH**, Beijnen JH, Huitema AD. Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. *Invest New Drugs* 2014; 32: 913-27
- 667 Hendriks JJ, Rosing H, Schinkel AH, **Schellens JH**, Beijnen JH. Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays. *Bioanalysis* 2014; 6: 993-1010
- 668 Jager NG, Rosing H, **Schellens JH**, Beijnen JH, Linn SC. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. *Breast Cancer Res Treat* 2014; 146: 137-44
- 669 Boix-Perales H, Borregaard J, Jensen KB, Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, **Schellens JH**, Pignatti F. The European Medicines Agency review of pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist* 2014; 19: 766-73
- 670 Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, **Schellens JH**, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarín E, Meresse V, Soria JC. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. *Clin Cancer Res* 2014; 20: 4251-61
- 671 Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, **Schellens JH**. Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183. *Invest New Drugs* 2014; 32: 1083-95
- 672 Opdam FL, Huitema AD, Beijnen JH, **Schellens JH**. Hyperglycaemia during treatment with everolimus. *Ned Tijdschr Geneeskd* 2014; 158: A7544
- 673 Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, **Schellens JH**. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-

small cell lung cancer after first line therapy. *Invest New Drugs* 2014; 33: 201-14

- 674 Meulendijks D, Dewit L, Tomaso NB, van Tinteren H, Beijnen JH, **Schellens JH**, Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. *Br J Cancer* 2014; 111: 1726-33
- 675 van Hasselt JG, van Eijkelenburg NK, Beijnen JH, **Schellens JH**, Huitema AD. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. *Pediatr Blood Cancer* 2014; 61: 2223-29
- 676 Crombag MR, de Vries Schultink AH, **Schellens JH**, Beijnen JH, Huitema AD. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. *Drugs Aging* 2014; 31: 737-47
- 677 Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, **Schellens JH**, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB. Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study. *Clin Cancer Res* 2014; 20: 5663-71
- 678 Kip AE, Balasegaram M, Beijnen JH, **Schellens JH**, de Vries PJ, Dorlo TP. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. *Antimicrob Agents Chemother* 2014; 59: 1-14
- 679 Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, **Schellens JH**, Beijnen JH. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. *Invest New Drugs* 2014; 33: 233-40
- 680 Jager NG, Rosing H, **Schellens JH**, Beijnen JH. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. *Bioanalysis* 2014; 6: 2481-514
- 681 Lassen U, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, **Schellens JH**, Hansen A, Jonker D, Simcox ME, Schostack K, Bottino D, Zhong H, Roessler M, Vega-Harrington S, Jarutat T, Geho D, Wang K, DeMario M, Goss G. A Phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. *Clin Cancer Res* 2014; 21: 258-66
- 682 Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, **Schellens JH**, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. *Br J Clin Pharmacol* 2014; 79: 809-19
- 683 Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Hooiveld MJ, Neven P, Raaijmakers JA, **Schellens JH**. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. *Eur J Cancer Care (Engl)* 2014; 24: 340-54
- 684 Jager NG, Rosing H, **Schellens JH**, Beijnen JH. Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects. *Bioanalysis* 2014; 6: 2999-3009
- 685 Nijenhuis CM, Rosing H, **Schellens JH**, Beijnen JH. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS. *Bioanalysis* 2014; 6: 3215-24
- 686 Meulendijks D, Khan S, Koks CH, Huitema AD, **Schellens JH**, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. *Eur J Clin Pharmacol* 2015; 71: 357-61
- 687 Dolman ME, Westerhout EM, Hamdi M, **Schellens JH**, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. *J Pharm Biomed Anal* 2015; 107: 403-08
- 688 Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, **Schellens JH**. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. *Br J Clin Pharmacol* 2015; 80: 253-66

- 689 Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, **Schellens JH**. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. *Cancer Chemother Pharmacol* 2015; 75: 763-72
- 690 Derissen EJ, Hillebrand MJ, Rosing H, **Schellens JH**, Beijnen JH. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. *J Pharm Biomed Anal* 2015; 110: 58-66
- 691 Herbrink M, Nuijen B, **Schellens JH**, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. *Cancer Treat Rev* 2015; 41: 412-22
- 692 Kordes S, Klumpen HJ, Weterman MJ, **Schellens JH**, Richel DJ, Wilmink JW. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. *Cancer Chemother Pharmacol* 2015; 75: 1135-41
- 693 Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, **Schellens JH**. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. *Bioanalysis* 2015; 7: 519-29
- 694 Meulendijks D, Tomaso NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH, **Schellens JH**, Cats A. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. *Br J Cancer* 2015; 112: 1358-66
- 695 Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, **Schellens JH**, Zivi A, Crespo M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, Moore D, Alumkal JJ, Dymond A, Dickinson PA, Ranson M, Clack G, de Bono J, Elliott T. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. *Invest New Drugs* 2015; 33: 679-90
- 696 Braam HJ, **Schellens JH**, Boot H, van Sandick JW, Knibbe CA, Boerma D, van Ramshorst B. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. *Crit Rev Oncol Hematol* 2015; 95: 282-96
- 697 van Hasselt JG, Allegaert K, Van Calsteren K, Beijnen JH, **Schellens JH**, Huitema AD. Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy". *Biomed Res Int* 2015; 124035
- 698 Liberti L, Stolk P, McAuslane JN, **Schellens J**, Breckenridge AM, Leufkens H. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications. *Oncologist* 2015; 20: 683-91
- 699 Jager NG, Linn SC, **Schellens JH**, Beijnen JH. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. *Clin Breast Cancer* 2015; 15: 241-44
- 700 Jager NG, Rosing H, Linn SC, **Schellens JH**, Beijnen JH. Dried blood spot self-sampling at home for the individualization of tamoxifen treatment: a feasibility study. *Ther Drug Monit* 2015; 37: 833-36
- 701 Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, **Schellens JH**, Huitema AD. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. *Pharmacol Res Perspect* 2015; 3:e00131
- 702 Frederix GW, Hovels AM, Severens JL, Raaijmakers JA, **Schellens JH**. Threshold value for reimbursement of costs of new drugs: cost-effectiveness research and modelling are essential links. *Drempelwaarde bij vergoeding van nieuwe medicatie. Ned Tijdschr Geneesk* 2015; 159: A7728
- 703 Sobral-Leite M, Wesseling J, Smit VT, Nevanlinna H, van Miltenburg MH, Sanders J, Hofland I, Blows FM, Coulson P, Patrycja G, **Schellens JH**, Fagerholm R, Heikkila P, Aittomaki K, Blomqvist C, Provenzano E, Ali HR, Figueroa J, Sherman M, Lissowska J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Phillips KA, Couch FJ, Olson JE, Vachon C, Visscher D, Brenner H, Butterbach K, Arndt V, Holleczeck B, Hoening MJ, Hollestelle A, Martens JW, van Deurzen CH, van de Water B, Broeks A, Chang-Claude J, Chenevix-Trench G, Easton DF, Pharoah PD, Garcia-Closas M, de Graauw M, Schmidt

MK. Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. *BMC Med* 2015; 13: 156

- 704 Kip AE, Rosing H, Hillebrand MJ, Castro MM, Gomez MA, **Schellens JH**, Beijnen JH, Dorlo TP. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2015; 998-999: 57-62
- 705 van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. *Br J Cancer*. 2015;113:396-402
- 706 Meulendijks D, Jacobs BA, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, Beijnen JH, Cats A, **Schellens JH**. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele. *Int J Cancer* 2016; 138: 245-53
- 707 Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, **Schellens JH**, Guchelaar HJ. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. *Pharmacogenomics* 2015; 16: 1-10
- 708 Bazargani YT, de Boer A, **Schellens JH**, Leufkens HG, Mantel-Teeuwisse AK. Essential medicines for breast cancer in low and middle income countries. *BMC Cancer*. 2015; 15: 591
- 709 Kerklaan BM, Lolkema MP, Devriese LA, Voest EE, Nol-Boekel A, Mergui-Roelvink M, Langenberg M, Mykulowycz K, Stoebenau J, Lane S, Legenne P, Wissel P, Smith DA, Giantonio BJ, **Schellens JH**, Witteveen PO. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. *Br J Cancer* 2015; 113: 706-15
- 710 Hendriks JJ, Lagas JS, Song JY, Rosing H, **Schellens JH**, Beijnen JH, Rottenberg S, Schinkel AH. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. *Int J Cancer* 2015; 138: 758-69
- 711 van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, **Schellens JH**, Huitema AD. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. *CPT Pharmacometrics Syst Pharmacol* 2015; 4: 374-85
- 712 van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, **Schellens JH**, Huitema AD. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. *CPT Pharmacometrics Syst Pharmacol* 2015; 4: 386-95
- 713 Nijenhuis CM, Lucas L, Rosing H, **Schellens JH**, Beijnen JH, Gorman SH, Burke SM, Campbell DA, Chapple MW, Yousey TH, Mulvana DE. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'-des-methyl and cephalotaxine metabolites in human plasma and urine. *J Chromatogr B Analyt Technol Biomed Life Sci* 2015; 1002: 152-59
- 714 van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD, Rosing H, Tibben MM, Keessen M, Rehorst H, Beijnen JH, **Schellens JH**. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. *Invest New Drugs* 2015; 33: 1197-205
- 715 Meulendijks D, Lassen U, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker D, Hansen A, Simcox ME, Schostack K, Bottino D, Zhong H, Roessler M, Vega-Harring S, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, **Schellens JH**. Exposure and Tumor Fn14 expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-positive Solid Tumors. *Clin Cancer Res* 2015; 22:858-67
- 716 Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema M, Voest E, Langenberg MH, Fleitas T, Cervantes A, de Jonge MJ, Sleijfer S, Mau-Sørensen M, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, **Schellens JH**, Weisser M, Lassen U. First-in-human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal

- Antibody, in Patients with Metastatic or Advanced HER3-positive Solid Tumors. *Clin Cancer Res* 2015; 22: 877-85
- 717 Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, **Schellens JH**, Brandsma D. Strategies to target drugs to gliomas and CNS metastases of solid tumors. *J Neurol* 2015; 263: 428-40
- 718 Deenen MJ, Meulendijks D, Boot H, Legdeur MJ, Beijnen JH, **Schellens JH**, Cats A. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. *Cancer Chemother Pharmacol* 2015; 76: 1285-95
- 719 Rood JJ, van Hoppe S, Schinkel AH, **Schellens JH**, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. *J Pharm Biomed Anal* 2015; 118: 123-131
- 720 Keusters WR, Frederix GW, de Weger VA, Beijnen JH, Hövels AM, **Schellens JH**. Decrease of Patient Costs in the Netherlands: a Cost of Illness Study in Metastatic Non Small Cell Lung Cancer (NscLc). *Value Health* 2015; 18: A446
- 721 Henricks LM, **Schellens JH**, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. *Cancer Treat Rev* 2015; 41: 859-67
- 722 Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, **Schellens JH**, Brandsma D. EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. *Neuro Oncol* 2015; 18: 855-62
- 723 Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, **Schellens JH**. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. *J Clin Oncol* 2015; 34: 227-34
- 724 Munster PN, Aggarwal R, Hong D, **Schellens JH**, van der Noll R, Specht J, Witteveen PO, Werner T, Dees EC, Bergsland EK, Agarwal N, Kleha JF, Durante M, Adams LM, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-kinase inhibitor, in Patients with Advanced Solid Tumor Malignancies. *Clin Cancer Res* 2015; 22: 1932-9
- 725 Yu H, Hendriks JJ, Rottenberg S, **Schellens JH**, Beijnen JH, Huitema AD. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. *AAPS J* 2015; 18: 362-71
- 726 Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadè CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, **Schellens JH**. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. *Lancet Oncol* 2015; 16: 1639-50
- 727 van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. *Curr Colorectal Cancer Rep* 2015; 11: 335-44
- 728 Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, Tesselaar ME, Schellens JH, Cats A. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. *Invest New Drugs* 2016; 34: 119-28
- 729 Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. *Bioanalysis* 2016; 8: 123-34
- 730 Lunenburg CA, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JH, Gelderblom H. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. *Eur J Cancer* 2016; 54: 40-48

- 731 van Geel RM, Hendriks JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, Schellens JH, Burgers SA. Crizotinib-induced fatal fulminant liver failure. *Lung Cancer* 2016; 93: 17-19
- 732 Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. *Trials* 2016; 17: 293
- 733 Derissen EJ, Jacobs BA, Huitema AD, Rosing H, **Schellens JH**, Beijnen JH. Exploring the intracellular pharmaco-kinetics of the 5-fluorouracil nucleotides during capecitabine treatment. *Br J Clin Pharmacol* 2016; 81: 949-57
- 734 Crombag MR, Joerger M, Thürlimann B, **Schellens JH**, Beijnen JH, Huitema AD. Pharmacokinetics of selected anticancer drugs in elderly cancer patients: focus on breast cancer. *Cancers (Basel)* 2016; 8
- 735 Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, **Schellens JH**. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. *Eur J Cancer* 2016; 54: 120-30
- 736 Kip AE, Rosing H, Hillebrand MJ, Blessen S, Mengesha B, Diro E, Hailu A, **Schellens JH**, Beijnen JH, Dorlo TP. Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection. *Antimicrob Agents Chemother* 2016; 60: 2081-89
- 737 Cirkel GA, Kerklaan BM, Vanhoutte F, Van der Aa A, Lorenzon G, Namour F, Pujuguet P, Darquenne S, de Vos FY, Snijders TJ, Voest EE, **Schellens JH**, Lolkema MP. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. *Invest New Drugs* 2016; 34: 184-92
- 738 Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, **Schellens JH**. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. *Int J Cancer* 2016; 138: 2752-61
- 739 Sparidans RW, van Hoppe S, Rood JJ, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016; 1012-1013
- 740 van Geel RM, Hendriks JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, **Schellens JH**, Burgers SA. Crizotinib-induced fatal fulminant liver failure. *Lung Cancer* 2016; 93: 17-19
- 741 de Vries Schultink AH, Suleiman AA, **Schellens JH**, Beijnen JH, Huitema AD. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. *Eur J Clin Pharmacol* 2016; 72: 645-53
- 742 Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, **Schellens JH**, Beijnen JH. The use of dried blood spots for pharmacokinetic monitoring of vemurafenib treatment in melanoma patients. *J Clin Pharmacol* 2016; 56: 1307-12
- 743 van Brummelen EM, Huitema AD, van Werkhoven E, Beijnen JH, **Schellens JH**. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years. *J Pharmacokinet Pharmacodyn* 2016; 43: 235-42
- 744 Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, **Schellens JH**, Grootsholten C, Tesselaar ME, Cats A. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. *Cancer* 2016; 122: 1434-43
- 745 Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, **Schellens JH**, Isacoff EY, Sali A, Chen

T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. *Nat Commun* 2016; 7: 10880

- 746 Nijenhuis CM, Lucas L, Rosing H, Robertson P Jr, Hellriegel ET, **Schellens JH**, Beijnen AJ. Metabolite profiling of (14)C-omacetaxine mepesuccinate in plasma and excreta of cancer patients. *Xenobiotica* 2016: 1-11
- 747 Dubbelman AC, Nijenhuis CM, Jansen RS, Rosing H, Mizuo H, Kawaguchi S, Critchley D, Shumaker R, **Schellens JH**, Beijnen JH. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison. *Invest New Drugs* 2016; 34: 300-18
- 748 Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, **Schellens JH**. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of $\alpha 2$ integrin inhibitor E7820 in patients with advanced solid tumors. *Invest New Drugs* 2016; 34: 329-37
- 749 Nijenhuis CM, Haverkate H, Rosing H, **Schellens JH**, Beijnen JH. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry. *J Pharm Biomed Anal* 2016; 125: 270-79
- 750 Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P Jr, **Schellens JH**, Beijnen JH. Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [*J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.* 893-894 (2012) 92-100]. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016; 1020: 168-69
- 751 Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, **Schellens JH**, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. *Cancer Chemother Pharmacol* 2016; 77: 1201-17
- 752 Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, **Schellens JH**. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. *Br J Clin Pharmacol* 2016; 82: 706-16
- 753 Deenen MJ, Cats A, Severens JL, Beijnen JH, **Schellens JH**. Reply to T. Magnes et al. *J Clin Oncol* 2016; 34: 2434-35
- 754 Jacobs BA, Rosing H, de Vries N, Meulendijks D, Henricks LM, **Schellens JH**, Beijnen JH. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. *J Pharm Biomed Anal* 2016; 126: 75-82
- 755 Sparidans RW, Kort A, Schinkel AH, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016; 1023-1024: 24-29
- 756 Nijenhuis CM, **Schellens JH**, Beijnen JH. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. *Drug Metab Rev* 2016; 48: 266-80
- 757 Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P Jr, Rosing H, Spiegelstein O, **Schellens JH**. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors. *Invest New Drugs* 2016; 34: 565-74
- 758 Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, **Schellens JH**, Sleijfer S, Lolkema MP, Voest EE. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies. *Ann Oncol* 2016; 27: 1638-43
- 759 Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, **Schellens JH**, Beijnen JH. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016; 1027: 1-10

- 760 Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernardis R, **Schellens JH**, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. *Cancer Res* 2016; 76: 4504-15
- 761 Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, **Schellens JH**, Linn SC. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. *Trials* 2016; 17: 293
- 762 Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, **Schellens JH**. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. *JAMA Oncol* 2016; 2: 1030-37
- 763 Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, **Schellens JH**, Beijnen JH. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. *J Clin Pharmacol* 2016; in press
- 764 van Brummelen EM, Ros W, Wolbink G, Beijnen JH, **Schellens JH**. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. *Oncologist* 2016; in press
- 765 Rood JJ, **Schellens JH**, Beijnen JH, Sparidans RW. Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. *J Pharm Biomed Anal* 2016; in press
- 766 Rood JJ, van Bussel MT, **Schellens JH**, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectro-metric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016; 1031: 80-85
- 767 Verheijen RB, Bins S, Mathijssen RH, Lolkema M, van Doorn L, **Schellens JH**, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. *Clin Cancer Res.* 2016; in press
- 768 Sawicki E, Beijnen JH, **Schellens JH**, Nuijen B. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. *Int J Pharm* 2016; 511: 765-73
- 769 Yu H, van Erp N, Bins S, Mathijssen RH, **Schellens JH**, Beijnen JH, Steeghs N, Huitema AD. Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. *Clin Pharmacokinet* 2016; in press
- 770 Meulendijks D, Henricks LM, van Kuilenburg AB, Jacobs BA, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, **Schellens JH**. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. *Cancer Chemother Pharmacol* 2016; in press
- 771 Herbrink M, **Schellens JH**, Beijnen JH, Nuijen B. Inherent formulation issues of kinase inhibitors. *J Control Release.* 2016; 239: 118-27
- 772 Meulendijks D, Cats A, Beijnen JH, **Schellens JH**. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? *Cancer Treat Rev* 2016; 50: 23-34
- 773 Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, **Schellens JH**, Shapiro GI. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. *J Clin Oncol* 2016; in press
- 774 Sparidans RW, Rosing H, Rood JJ, **Schellens JH**, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR

inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016; 1033-1034: 390-98

- 775 Bins S, Cirkel GA, Gadellaa-van Hooijdonk CG, Weeber F, Nijman IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, **Schellens JH**, Voest EE, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP. Implementation of a multicenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies. *Oncologist* 2016 in press

Reviews and editorials

- 1 Kuppens IE, Beijnen J, **Schellens JHM**. Topoisomerase I inhibitors in the treatment of gastro-intestinal cancer: from intravenous to oral administration. *Clin Colorectal Cancer* 2004; 4: 163-80
- 2 Joerger M, **Schellens JHM**, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. *Methods Find Exp Clin Pharmacol*. 2004; 26: 531-45
- 3 Beijnen JH, **Schellens JHM**. Drug Interactions in Oncology. *Lancet Oncology* 2004; 5: 489-96
- 4 Appels NM, Beijnen JH, **Schellens JHM**. Development of farnesyl transferase inhibitors: a review. *Oncologist* 2005; 10: 565-78
- 5 Siegel-Lakhai WS, Beijnen JH, **Schellens JHM**. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). *Oncologist* 2005; 10: 579-89
- 6 Kuppens IE, Breedveld P, Beijnen JH, **Schellens JHM**. Modulation of oral drug bioavailability. *Cancer Invest*. 2005; 23: 443-64
- 7 **Schellens JHM**. Challenges of oral chemotherapy, *Clin. Adv Hematology& Oncology* 2005; 3: 99-100
- 8 De Jonge ME, Huitema AD, **Schellens JHM**, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaption: a review. *Clin Pharmacokinet*. 2005 44:147-73
- 9 Triesscheijn M, Baas P, **Schellens JHM**, Stewart FA. Photodynamic therapy in oncology. *Oncologist* 2006; 11: 1034-44
- 10 Boekhout AH, Beijnen JH, **Schellens JHM**. Symptoms and treatment in cancer therapy-induced early menopause. *Oncologist* 2006; 11: 641-54
- 11 Meijerman I, Beijnen JH, **Schellens JHM**. Herb-drug interactions in oncology: focus on mechanisms of induction. *Oncologist* 2006; 11: 742-52
- 12 Van den Berg JH, Beijnen JH, Balm AJ, **Schellens JHM**. Future opportunities in preventing cisplatin induced ototoxicity. *Cancer Treat Rev*. 2006; 32: 390-97
- 13 Beumer JH, Beijnen JH, **Schellens JHM**. Mass balance studies, with a focus on anticancer drugs. *Clin Pharmacokinet*. 2006; 45: 33-58
- 14 Engwegen JYMN, Gast MCW, **Schellens JHM**, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. *Trends Pharmacol Sci*. 2006; 27: 251-59
- 15 Breedveld P, Beijnen JH, **Schellens JHM**. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. *Trends Pharmacol Sci*. 2006; 27: 17-24
- 16 De Kogel Ch, **Schellens JHM**. Imatinib. *Oncologist*. 2007; 12: 1390-94
- 17 **Schellens JHM**, Looking back at EACPT2007. *Basic Clin Pharmacol Toxicol*. 2007; 101: 393-4
- 18 Marchetti S, **Schellens JHM**. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. *Br J Cancer* 2007; 97: 577-81
- 19 Marchetti S, Mazzanti R, Beijnen JH, **Schellens JHM**. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). *Oncologist* 2007; 12: 927-41
- 20 Vink SR, Van Blitterswijk WJ, **Schellens JHM**, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. *Cancer treat Rev*. 2007; 33: 191-202
- 21 **Schellens JHM**. Capecitabine. *Oncologist* 2007; 12: 152-55
- 22 Kemper EM, van Kan HJ, Speelman P, de Gans K, Beijnen JH, **Schellens JHM**. Severe phenytoin intoxication in patients with hypoalbuminaemia. *Ned Tijdschr Geneesk*. 2007; 151: 138-41
- 23 **Schellens JHM**, Beijnen JH. Management recommendations in patients with methotrexate intoxication. *Ned Tijdschr Geneesk* 2007; 151: 337-41
- 24 Harmsen S, Meijerman I, Beijnen JH, **Schellens JHM**. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. *Cancer Treat Rev*. 2007; 33: 369-80
- 25 Keizer RJ, Huitema AD, Damen CW, **Schellens JHM**, Beijnen JH. The pharmacokinetics of monoclonal antibodies. *Ned Tijdschr Geneesk* 2007; 151: 683-88
- 26 **Schellens JHM**. PARP1: de achilleshiel van de BRCA-deficiënte tumor. *Medische Oncologie* 2008; 5: 29-31

Books and chapters in books

1. Van Rijswijk REN, **Schellens JHM**, Van der Vijgh WJF, Vermorken JB. Maligne aandoeningen. In: Farmacologie (Sitsen JMA, Smits JFM, Smits P, Cohen AF, Van Bortel LM, eds). Elsevier gezondheidszorg, Maarssen 2004; 499-524
2. **Schellens JHM**. Clinical implications and mechanisms of variability in the response to anticancer agents. Chapter 3, 30-40. In: Schellens JHM, McLeod HL, DR Newell (eds) Cancer Clinical Pharmacology. Oxford; New York: Oxford University Press 2005
3. Milano G, **Schellens JHM**. Pyrimidine antimetabolites. Chapter 5, 51-62. In: Schellens JHM, McLeod HL, DR Newell (eds) Cancer Clinical Pharmacology. Oxford; New York: Oxford University Press 2005
4. Lakhai WS, Beijnen JH, **Schellens JHM**. Novel tyrosine kinase inhibitors: focus on Imatinib and gefitinib. Chapter 14, 198-215. In: Schellens JHM, McLeod HL, DR Newell (eds) Cancer Clinical Pharmacology. Oxford; New York: Oxford University Press 2005
5. Verweij J, **Schellens JHM**. Klinische onderzoeksmethodologie in de oncologie. In: Van de Velde CJH, van Krieken JHJM, de Mulder PHM, Vermorken JB, editors. Oncologie. 7th ed. Houten: Bohn Stafleu van Loghum 2005; 125-130
6. **Schellens JHM**. Variabiliteit in 'gevoeligheid' van farmaca. 2^e Druk. In: Algemeen Farmacologie. (J.M. van Ree, D.D. Breimer, eds), Elsevier Gezondheidszorg, Maarssen 2006; 159-181
7. Marchetti S, Beijnen JH, Mazzanti R, **Schellens JHM**. Clinical relevance: drug-drug interactions, pharmacokinetics, pharmacodynamics, and toxicity. In: Drug transporters: Molecular Characterization and Role in Drug Disposition, eds. Guofeng You & Marilyn E. Morris, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2007; 747-880
8. **Schellens JHM**, Mathijssen AHJ. Klinische onderzoeksmethodologie in de oncologie. In: Van de Velde CJH, van Krieken JHJM, de Mulder PHM, Vermorken JB, editors. Oncologie. 9th ed. Houten: Bohn Stafleu van Loghum 2009; in press
9. Cohen AF, Danhof M, Greef de HJMM, IJzerman AP, Kenter MJH, **Schellens JHM**, Sitsen JMA. Geneesmiddelen. In: Farmacologie (Sitsen JMA, Cohen AF, Franson KL, Smits P, Struijker Boudier HAJ, Van Bortel LM.) Elsevier gezondheidszorg, Maarssen 2009; 13-64
10. Oostendorp RL, Beijnen JH, **Schellens JHM**. The role of abc transporters at the intestinal barrier. In: ABC transporters and multidrug resistance. Edited by Boumendjel A, Boutonnat J, Robert J. 2009; 385-409

Unrefereed and other lab and clinical publications

1. Zandvliet AS, Bosch TM, **Schellens JHM**, Beijnen JH. Speuren naar de beste correlatie met bijwerkingen. Pharm Weekbl 2003; 138: 1323-30
2. De Jonge ME, Huitema ADR, Beijnen JH, **Schellens JHM**, Rodenhuis S. Succesvolle "rechallenge" met chromoglicaat. Overgevoeligheidsreacties bij Chemotherapie. Pharm Weekbl 2003; 138: 874-9
3. **Schellens JHM**. Inhibitors of drug transport proteins shed light on oral treatment of cancer. Conceptuur 2004; 40: 16-7
4. Jacobs BS, Klijn JS, Logman JFS, **Schellens JHM**. Epoëtine als ondersteuning in de behandeling van kanker: kwaliteit van leven verbeterend of levensgevaarlijk. Pharm Weekbl 2004; 139: 1714-6
5. Kaouass EG, Kustura A, Hoebe DM, Labadie J, **Schellens JHM**. Angineuze klachten bij het gebruik van fluorouracil en capecitabine. Pharm Weekbl 2004; 139: 1604-7
6. Matheij CAM, Putto MRCC, Najak A, **Schellens JHM**. Niet zonnen, niet roken, wel screenen. Pharm Weekbl 2004; 139: 1572-8
7. Raghoebarsingh W, Sanders SJWJ, De Vries LE, **Schellens JHM**. Behoud van fertiliteit na chemotherapie bij prepubertaire kinderen. Pharm Weekbl 2004; 139: 1526-9
8. Thuis IJT, Lakhai WS, **Schellens JHM**, Beijnen JH. Erlotinib houdt EGFR aan de teugel. Pharm Weekbl 2004; 139: 1426-8
9. Denissen JFPM, Tanwir MK, Woi A Sioe WJ, **Schellens JHM**. Let op vocht en interacties. Pharm Weekbl 2004; 139: 1358-62
10. Van Leeuwen RWF, Herrewijn D, Westerman B, **Schellens JHM**. Met profylaxe pakt rechallenge goed uit. Pharm Weekbl 2004; 139: 1240-4
11. Grijzen MC, Köhler TC, Van Vliet AC, Werkman GM, **Schellens JHM**. Tintelingen sluipen binnen. Pharm Weekbl 2004; 139: 1133-7
12. Bouwman K, Gast MCW, Bonfrer JMG, **Schellens JHM**, Beijnen JH. Proteomics in de oncologie. Pharm Weekbl 2004; 139: 879-84
13. **Schellens JHM**, Beijnen JH. Patiënt heeft voordeel bij paclitaxel in orale toedieningsvorm. Med Oncologie 2004; 7: 25
14. Beijnen JH, **Schellens JH**. Geneesmiddeleninteracties met oncolytica. Pharm Weekbl 2004; 139: 656-60
15. **Schellens JHM**, Beijnen JH. Toxiciteit van cytostatica: Soorten toxiciteit waarop de patiënt zich moet voorbereiden. Pharm Weekbl 2004; 139: 644-9
16. Verheggen BG, Bocxe JTH, Bergsma R, **Schellens JHM**. Rabdomyolyse als bijwerking van statines.

- Pharm Weekbl 2004; 139: 836-40
17. Nijland HMJ, Huitema ADR, Otten JMJB, **Schellens JHM**, Beijnen JH. Overzicht van interacties tussen oncolytica en orale anticoagulantia: ernstige gevolgen. Pharm Weekbl 2005; 140: 1442-7
 18. Crul M, Van Zandwijk N, Beijnen JH, **Schellens JHM**. Klinische en preklinische farmacologie van de combinatie cisplatine en gemcitabine. Pharm Weekbl 2005; 140: 369-71
 19. **Schellens JHM**. Misleidende reclame voor OxyContin. Pharm Weekbl 2005; 140: 196
 20. Berghauer Pont LME, Minjon L, Mooiman KD, **Schellens JHM**. Tromboseprofylaxe bij kankerpatiënten. Pharm Weekbl 2007; 16: 30-1
 21. Gast MCW, Engwegen JYMN, Helgason HH, **Schellens JHM**, Beijnen JH. 'Clinical proteomics' in de oncologie. Ned Tijdschrift voor Oncologie 2007; 4: 140-51
 22. **Schellens JHM**. Targeted drugs. Medische Oncologie 2007; 1: 32-3
 23. **Schellens JHM**, Beijnen JH, Haanen JBAG. Langer progressievrij bij nierkanker. Pharm Weekbl 2007; 6: 34-5
 24. Beijnen JH, **Schellens JHM**. Recente ontwikkelingen in de medicamenteuze behandeling van kanker. Pharm Weekbl 2007; 4: Wetenschappelijk Platform 1: 2-7
 25. **Schellens JHM**. Zelfdenkende medicijnen. GezondNU. 2008; 2: 28-31
 26. **Schellens JHM**. Informatie naar en samenwerking met patiënten- en consumentenorganisaties. Openheid van zaken. De werkzaamheden van het College ter Beoordeling van Geneesmiddelen. 2008; 107-09
 27. Beijnen JH, **Schellens JHM**. Drug interactions in oncology. EJHP Practice. 2008; 13-14
 28. Gouverneur BJGM, Huitema ADR, **Schellens JHM**, Beijnen JH. Fosaprepitant uitkomst bij slikproblemen. Pharm Weekbl 2009; 40: 28-31
 29. Aleman J, Huitema ADR, **Schellens JHM**, Beijnen JH. Mechanismen van resistentie tegen EGFR/HER2-antilichamen. Pharm Weekbl 2009; 42: 172-77
 30. Boss DS, Beijnen JH, **Schellens JHM**. Een nieuwe strategie tegen kanker: PARP-remmers. SCRIPT Oncologie 2009; 4: 1-3
 31. Hendriks JJMA, **Schellens JHM**, Beijnen JH. Methylnaltrexon bij darmfunctiestoornissen door opioïdengebruik. Pharm Weekbl 2009; 47: 192-98
 32. Goey AKL, **Schellens JHM**, Beijnen JH, Huitema ADR. Dexrazoxaan bij anthracycline-geïnduceerde cardiotoxiciteit en anthracycline-extravasatie. Ned Tijdschr Geneesk 2010; 154
 33. Beijnen JH, **Schellens JHM**. Nieuwe orale oncolytica: 'the intravenous to oral switch'. Oncollectie 2012; 2: 9-14
 34. van Hasselt JGC, van den Heuvel MM, **Schellens JHM**, Beijnen JH, Brandsma D, Huitema ADR. Severe cannabinoid intoxication in a patient with non-small-cell lung cancer. Journal of Palliative Care 2012; 28: 60-61
 35. van Keep MML, Huitema ADR, **Schellens JHM**, Beijnen JH. Eribuline: nieuw oncolyticum voor de behandeling van gemetastaseerde borstkanker. PW Wetenschappelijk Platform 2013; 7: 10-14
 36. de Jager A, **Schellens JHM**, Beijnen JH, Huitema ADR. Trastuzumab emtansine (T-DM1): een anti-lichaamgeneesmiddelconjugaat voor gerichte behandeling van HER2-positieve gemetastaseerde borstkanker. PW Wetenschappelijk Weekbl 2013; 46: 132-5
 37. Huitema ADR, **Schellens JHM**, Beijnen JH. Monoklonaal antilichaam geleidt cytotoxische stof naar tumor. PW Wetenschappelijk Weekbl 2014; 1/2: 26-9
 38. Van Geel RMJM, Bernards R, Voest EE, Lolkema MPJK, Cats A, Sleijfer S, Eskens FALM, **Schellens JHM**. Innovatieve combinatie van doelgerichte middelen voor de behandeling van gemetastaseerd BRAF-gemuteerd colorectaal carcinoom. Ned Tijdschr Geneesk 2014; 2: 69-72
 39. Hendriks JJMA, Rosing H, Schinkel AH, **Schellens JHM**, Beijnen JH. Translationele farmacologie van oraal gegeven taxanen. Pharm Weekbl 2014; 149: 26-29

Patent filings

1. A combination of 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-isoquinoli-nyl)ethyl]phenyl]-4-acridinecarboxamide or a salt thereof and Paclitaxel and its analogs or derivatives. Filed: 2000
2. A method of improving of oral bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novem pharmaceutical composition for oral delivery of drugs. Filed: 2001
3. Development of the anticancer agent Kahalalide F. Filed: 2002
4. The effect of Bcrp1 (Abcg2) on the *in vivo* pharmacokinetics and brain penetration of Imatinib mesylate (Gleevec®): implications for the use of BCRP and P-gp inhibitors to enable the brain penetration of Imatinib in patients. Filed: 2004
5. Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-

yl)pyrimidin-2-ylamino)phenyl]-benzamide. Filed: 2006

6. Taxane Formulations Prepared By Spray Drying

The application in this third family relates only to taxane formulations prepared by spray drying, as in family 2. The application in this family is as follows:

Country	Application No.	Filing Date	Earliest Priority Date
PCT	PCT/GB2009/002068	24/08/2009	22/08/2008

7. Taxane Formulations and Taxane Formulations Prepared By Spray Drying

The applications in this second family relate to the same taxane formulations as in family 1 and also to taxane formulations prepared by spray drying. The effect of spray drying is to increase the solubility of the taxane. The applications in this family are as follows:

Country	Application No.	Filing Date	Earliest Priority Date
Argentina	P 09 01 03252	24/08/2009	22/08/2008
Chile	1766-2009	24/08/2009	22/08/2008
Venezuela	001569-09	24/08/2009	22/08/2008

8. Taxane Formulation and Taxane/CYP3A4 Inhibitor Combination

The applications in the first family relate to: taxane formulations to improve oral bioavailability; and the combination of a taxane and a CYP3A4 inhibitor to improve oral bioavailability. The applications in this family are as follows:

Country	Application No.	Filing Date	Earliest Priority Date
PCT	PCT/GB2008/002854	22/08/2008	24/08/2007
US	12/197,432	25/08/2008	24/08/2007

9. UK Patent Application No 1115211.3 Sustained Release Formulation of Capecitabine. Filed: 2011

TRAINING OF GRADUATE (PhD) STUDENTS

1996	:	Co-promotor thesis research fellow Ma Jianguo
1998	:	Co-promotor thesis research fellow V.R. Nannan Panday
1998	:	Co-promotor thesis research fellow V.M.M. Herben
1999	:	Co-promotor thesis research fellow J. Meerum Terwoegt
2000	:	Promotor thesis research fellow Th. Kerbusch
2001	:	Promotor thesis research fellow M.M. Malingré
2002	:	Promotor thesis research fellow N. Schoemaker
2002	:	Promotor thesis research fellow H. Bardelmeijer
2002	:	Promotor thesis research fellow Ch. Van Kesteren
2002	:	Promotor thesis research fellow M. Crul
2002	:	Promotor thesis research fellow C.M.F. Kruijtzter
2002	:	Promotor thesis research fellow H.J.G.D. van den Bongard
2004	:	Promotor thesis research fellow E. Stokvis
2004	:	Promotor thesis research fellow E.F.A. Brandon
2004	:	Promotor thesis research fellow J.M. Rademaker-Lakhai
2004	:	Promotor thesis research fellow J.H. Beumer
2004	:	Promotor thesis research fellow I.E.L.M. Kuppens
2005	:	Promotor thesis research fellow N.M.G.M. Appels
2005	:	Promotor thesis research fellow W.S. Siegel-Lakhai
2005	:	Promotor thesis research fellow P. Breedveld
2006	:	Promotor thesis research fellow T.M. Bosch
2006	:	Promotor thesis research fellow M. Triesscheijn
2007	:	Promotor thesis research fellow A. Zandvliet
2007	:	Promotor thesis research fellow E. Brouwers

2007	:	Promotor thesis research fellow M. Jörger
2008	:	Promotor thesis research fellow J.Y.M.N. Engwegen
2008	:	Promotor thesis research fellow L. Vainchtein
2008	:	Promotor thesis research fellow S. Veltkamp
2009	:	Promotor thesis research fellow R. Oostendorp
2009	:	Promotor thesis research fellow M.C. Gast
2009	:	Promotor thesis research fellow S. Harmsen
2009	:	Promotor thesis research fellow C.W.N. Damen
2009	:	Promotor thesis research fellow R.S. Jansen
2009	:	Promotor thesis research fellow D.S. Boss
2010	:	Promotor thesis research fellow M.H.G. Langenberg
2010	:	Promotor thesis research fellow I. van den Broek
2010	:	Promotor thesis research fellow R.J. Keizer
2011	:	Promotor thesis research fellow M.J. Deenen
2011	:	Promotor thesis research fellow S.L.W. Koolen
2011	:	Promotor thesis research fellow A.H. Boekhout
2011	:	Promotor thesis research fellow S.F. Teunissen
2011	:	Promotor thesis research fellow L.A. Devriese
2012	:	Promotor thesis research fellow H.J. Klümpen
2012	:	Promotor thesis research fellow A.C. Dubbelman
2012	:	Promotor thesis research fellow T. Janssens
2013	:	Promotor thesis research fellow N.A. Lankheet
2013	:	Promotor thesis research fellow S.M. Leijen
2013	:	Promotor thesis research fellow G.W.J. Frederix
2013	:	Promotor thesis research fellow A.K.L. Goey
2013	:	Promotor thesis research fellow F.E. Stuurman
2013	:	Promotor thesis research fellow J. Meulenaar
2013	:	Promotor thesis research fellow J.J. Moes
2013	:	Promotor thesis research fellow S. Marchetti
2013	:	Promotor thesis research fellow K.D. Mooiman
2014	:	Promotor thesis research fellow J.G.C. van Hasselt
2014	:	Promotor thesis research fellow J.J.M.A. Hendrikx
2014	:	Promotor thesis research fellow N.G.L. Jager
2014	:	Promotor thesis research fellow R. van der Noll
2015	:	Promotor thesis research fellow B. Milojkovic Kerklaan
2016	:	Promotor thesis research fellow D. Meulendijks
2016	:	Promotor thesis research fellow C.M. Nijenhuis
2016	:	Promotor thesis research fellow H. Yu
2016	:	Promotor thesis research fellow R.M.J.M. van Geel

PROFESSIONAL ACTIVITIES

Membership of professional bodies/learned societies

National administrative responsibility

2002 - present	Member Section Clinical Pharmacology of the Dutch Society of Internal Medicine (NIV)
2002 - 2005	Member Scientific Advisory Board of the Dutch Cancer Society
2000 - 2012	Chairman Dutch Society for Clinical Pharmacology and Biopharmacy
1996 - 2012	Board member of the Dutch Society for Clinical Pharmacology and Biopharmacy
1989 - 1991	Member of the Junior Board of the Dutch Society of Internal Medicine (JNIV)
1986 - 1989	Member of the Board of the Society of Medical Scientific Researchers (VMWO)

International administrative responsibility

2009 - 2011	Member of ESMO Faculty; principles of clinical trials
2003 - 2006	Chairman of the Pharmacology and Molecular Mechanisms Group of the EORTC
2000 - 2003	Secretary of the Pharmacology and Molecular Mechanisms Group of the EORTC
2000 - 2012	Member of the Executive Committee of the European Association for Clinical Pharmacology and Therapeutics

1999 - 2012	Council member of the European Association for Clinical Pharmacology and Therapeutics
1996 - 2010	Board member of the Pharmacology and Molecular Mechanisms Group of the EORTC
1996 - 2004	Member of the Early Clinical Study Group of the EORTC

Dutch medicines evaluation board (CBG-MEB)

1999 - 2016	Board member
-------------	--------------

European medicines evaluation board

2010 - 2016	Chairperson Scientific Advisory Group (SAG) Oncology (on behalf of The Netherlands CBG-MEB)
2007 - 2010	Vice chairperson Scientific Advisory Group (SAG) Oncology (on behalf of The Netherlands CBG-MEB)
2003 - 2016	Member Scientific Advisory Group (SAG) Oncology (on behalf of The Netherlands CBG-MEB)
2000 - present	Oncology expert advisory panel

Committee pharmaceutical products (= College voor Zorgverzekeringen – Commissie Farmaceutische Hulp: CVZ-CFH)

2005 - 2012	Chairman
-------------	----------

Membership of internal committees

1997 – 2005 & 2010 - present	Member of the Medical Ethics Committee (non-voting member for studies to which JHM Schellens is committed)
------------------------------	--

Membership of review/grant committees

2007 - 2010	Cancer Research UK grant review committee
2002 - 2005	Member Scientific Advisory Board of the Dutch Cancer Society

Educational activities

Outside the Institute

Teaching responsibility for university and graduate (i.e. PhD) students, Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.

Postgraduate courses Medical Therapy, Leiden University, The Netherlands.

Postgraduate courses Medical Oncology, University Florence, Italy.

At the Institute

Teaching responsibility for university and graduate (i.e. PhD) students.

2005 - present Authorized by the Dutch Society for Internal Medicine to train internists in Clinical Pharmacology

1997 - present Authorized by the Dutch Society for Clinical Pharmacology and Biopharmacy to train MD's and pharmacists in Clinical Pharmacology

Prizes and Honors

2003	Honorary Professor of Medical Oncology at the postgraduate School of Oncology, University of Florence, Italy
2006	Visiting Professor University of NC Chapel Hill, USA
2007	Honorary President of the European Association for Clinical Pharmacology and Therapeutics
2013	Honorary member Dutch Society of Clinical Pharmacology & Biopharmacy

Invited lectures (since 2003)

2016	ESMO 2016, Copenhagen (keynote)
2016	ASCO annual meeting, USA
2016	ESTRO35, Turin
2016	AACR annual meeting, USA (keynote)
2016	ESMO, Barcelona
2015	ECCO Vienna
2015	ASCO annual meeting, USA
2015	AACR annual meeting, USA (keynote)
2015	ESMO 2015, Spain (keynote)
2015	CDDF 8 th Alpine Conference, Austria
2014	8 th European Scientific Oncology Conference, Spain (keynote)
2014	ASCO annual meeting, USA
2014	AACR annual meeting, USA (keynote)
2014	Targeted Therapy, NVMO, Amersfoort (keynote)
2013	ASCO annual meeting, USA
2013	AACR annual meeting, USA (keynote)
2013	Targeted Therapy, NVMO, Amersfoort (keynote)
2012	Oncologiedagen, (Papendal) The Netherlands
2012	EORTC-NCI-AACR, Ireland
2012	7th European Spring Oncology Conference, Marbella, Spain
2012	ISPCC Pt, Verona, Italy
2012	FIGON, The Netherlands (keynote)
2012	ASCO annual meeting, USA
2012	ESMO 2012, Vienna (keynote)
2012	AACR annual meeting, USA (keynote)
2012	Targeted Anticancer Therapy, The Netherlands (keynote)
2011	ESMO, Sweden (keynote)
2011	ASCO annual meeting, USA
2011	Targeted Therapy, NVMO, Amersfoort (keynote)
2011	Boerhaave course Medical Therapy, PARP inhibitors, Leiden (keynote)
2010	ASCO annual meeting, USA
2010	ESMO 2010, Milan (keynote)
2010	Institut Gustave Roussy, Paris (keynote)
2009	ASCPT, Bethesda, USA (keynote)
2009	ASCO annual meeting, USA
2009	Dutch Medicine Board, The Hague (keynote)
2009	Dutch Internists Congress, Maastricht
2009	3 rd Dutch Medical Oncology congress, Papendal (keynote)
2008	EORTC-NCI-AACR, Switzerland
2008	8 th International Conference of Anticancer Research, Greece (keynote)
2008	Clinical phases of drug development: from phase 0 to phase IV and registration, the Netherlands (keynote)
2008	PUOZ NVZA, Bevacizumab, the Netherlands (keynote)
2008	Molecular Targets for Cancer, Norway (keynote)
2008	Eurocancer 2008, France (keynote)
2008	Molecular Pharmacology & Pathophysiology, France (keynote)
2008	ASCO annual meeting, USA (posterdiscussion session)
2008	AACR annual meeting; Meet the professor, session: Pharmagenetics and clinical implications (keynote)
2008	AACR annual meeting; Phase 0 studies, USA (keynote)
2007	ISPCC, (International Platinum conference), Italy (keynote)
2007	ASCO annual meeting, USA

2007 Targeted Anticancer Therapy, The Netherlands (keynote)
 2007 Free University medical Center, lecture department of Pharmacy, The Netherlands (keynote)
 2007 8th Eur. Assoc. Clin. Pharmacol & Ther. Biannual meeting, The Netherlands (keynote)
 2007 8th Eur. Assoc. Clin. Pharmacol & Ther., Biannual meeting, The Netherlands (pro-con discussion)
 2007 Eur. Assoc. Clin. Pharmacology & Ther. Spring meeting, Germany (keynote)
 2007 Medical Therapy, The Netherlands (keynote)
 2006 Course Postgraduate School of Pharmacy University NC, USA (keynote)
 2006 Lecture series GlaxoSmithKline, USA (keynote)
 2006 ASCO annual meeting, USA
 2006 Eur Assoc. Clin. Pharmacol. & Ther. Spring meeting, The Netherlands
 2006 Targeted Anticancer Therapy, The Netherlands (keynote)
 2006 Pharmacology and Molec. Mechanisms group-EORTC, United Kingdom
 2005 AACR annual meeting, USA
 2005 Medical Therapy, The Netherlands (keynote)
 2005 7th Eur. Assoc. Clin. Pharmacol & Ther. Biannual meeting (keynote)
 2004 FIGON, The Netherlands (keynote)
 2004 ASCO annual meeting, USA
 2003 Pharmacology and Molec. Mechanisms group-EORTC, Italy
 2003 Medical Therapy, The Netherlands (keynote)
 2003 Targeted Anticancer Therapy, The Netherlands (keynote)
 2003 6th Eur. Assoc. Clin. Pharmacol & Ther. Biannual meeting (keynote)

Meetings organized

2016 ESMO 2016, Copenhagen
 2015 Organizer of the 13th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
 2013 Organizer of the 12th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
 2013 Targeted Anticancer Therapy, Paris, France
 2012 36th ESMO Congress, Vienna, Austria
 2011 Organizer of the 11th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
 2010 35th ESMO Congress, Milan, Italy
 2009 Committee Scientific Advisory Committee, 9th International Congress of EACPT, Edinburgh, United Kingdom
 2009 Organizer of the 10th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
 2009 Targeted Anticancer Therapy 7th, Amsterdam, the Netherlands
 2008 Scientific Advisory Committee 6th International Symposium on Targeted Anticancer Therapies, Bethesda, USA
 2008 Faculty member AACR annual meeting
 2007 Organizer of the 9th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
 2007 Scientific Advisory Committee 5th International Symposium on Targeted Anticancer Therapies, Amsterdam, The Netherlands
 2007 Chairperson Organizing Committee VIIIth Conference of the European Association of Clinical Pharmacology and Therapeutics, Amsterdam, The Netherlands
 2007 Scientific Advisory Committee International Conference on Platinum Anticancer Drugs, Verona, Italy
 2006 Scientific Advisory Committee 4th International Symposium on Targeted Anticancer Therapies, Amsterdam, The Netherlands
 2005 Scientific advisory Committee Winter meeting PAMM-EORTC, Arcachon, France
 2005 Organizer of the 8th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
 2005 Scientific Advisory Committee 3rd International Symposium on Targeted Anticancer Therapies, Amsterdam, The Netherlands
 2005 Faculty member Annual Meeting AACR
 2005 Committee Scientific Advisory Committee, 7th International Congress of EACPT, Poznan, Poland
 2004 Scientific Advisory Committee Wintermeeting PAMM-EORTC, Bradford, United Kingdom
 2004 Scientific Advisory Committee 2nd International Symposium on Targeted Anticancer Therapies, Amsterdam, The Netherlands
 2004 Faculty member Annual Meeting ASCO
 2003 Scientific Advisory Committee Wintermeeting PAMM-EORTC, Florence, Italy
 2003 Organizer of the 7th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
 2003 Scientific Advisory Committee 1st International Symposium on Targeted Anticancer Therapies, Amsterdam, The Netherlands
 2003 Scientific Advisory Committee, 6th International Congress of EACPT, Istanbul, Turkey
 2002 Faculty member congress of the European Society for Medical Oncology. Nice, France

- 2002 Scientific Advisory Committee 1st International Symposium on signal transduction modulators in cancer therapy. Amsterdam, The Netherlands
- 2002 Faculty member Annual Meeting ASCO
- 2002 Scientific Advisory Committee Wintermeeting PAMM-EORTC, Copenhagen, Denmark
- 2001 Scientific Advisory Committee NCI-EORTC-AACR 12th Symposium on new drugs in cancer therapy, Orlando, Fl.
- 2001 Scientific Advisory Committee 5th International Congress of EACPT, Odense, Denmark
- 2001 Scientific Advisory Committee Wintermeeting PAMM-EORTC, Verona, Italy
- 2001 Organizer of the 5th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
- 1999 Faculty member Annual Meeting ASCO
- 1997 Organizer of the third Dutch Population Pharmacokinetic Workshop
- 1997 Organizer of the 4th Boerhaave Course on Drug Therapy, Leiden, The Netherlands
- 1996 Organizer of the second Dutch Population Pharmacokinetic Workshop
- 1996 Organizer and initiator of the first Dutch Population Pharmacokinetic Workshop
- 1996 Organizer of the second workshop "PAMM population approach initiative", Amsterdam The Netherlands
- 1995 Organizing Committee 7th International Symposium on Platinum and other metal coordination compounds in Cancer Chemotherapy (ISPC'95), Amsterdam, The Netherlands
- 1995 Organizer of the workshop "PAMM-population approach initiative", Amsterdam, The Netherlands
- 1995 Organizer of the third Boerhaave Course on Drug Therapy, Leiden , The Netherlands
- 1994 Organizer post-graduate course on Medical Oncology, The Netherlands
- 1993 Organizer of the second Boerhaave Course on Drug Therapy, Leiden , The Netherlands
- 1991 Organizer of the Boerhaave Course on Drug Therapy, Leiden , The Netherlands

Editorial boards

- 2015 Editor of "Medicamenteuze Therapie" (13th edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 2013 Editor of "Medicamenteuze Therapie" (12th edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 2011 – 2013 Editorial Board British Journal of Clinical Pharmacology
- 2011 Editor of "Medicamenteuze Therapie" (11th edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 2010 – 2013 Editorial Board Molecular Cancer Therapy
- 2009 - present Editorial Board "Annals of Oncology"
- 2009 Editor of "Medicamenteuze Therapie" (10th edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 2007 Proceedings Conference EACPT in Basic and Clinical Pharmacology and Toxicology
- 2006 - 2012 Editorial board "Metal-Based Drugs"
- 2006 Editor of "Medicamenteuze Therapie" (9th edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 2005 Editor of "Medicamenteuze Therapie" (8th edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 2004 - present Editorial board "Journal of Chemotherapy"
- 2003 Editor of "Medicamenteuze Therapie" (7th edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 2003 - 2011 Editorial Board "Therapeutic Drug Monitoring"
- 2002 - 2005 Editorial Board "Journal of Clinical Oncology"
- 2001 - 2012 Editorial Board "Molecular Cancer Therapeutics"
- 2001 - present Editorial Board "Cancer Chemotherapy and Pharmacology"
- 2000 - present Editorial board "The Oncologist"
- 1998 - present Editorial board "Investigational New Drugs"
- 1997 Editor of "Medicamenteuze Therapie" (fourth edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 1997 Co-editor textbook on "Cancer Clinical Pharmacology"
- 1996 - 1999 Editorial Board "International Journal of Oncology"
- 1995 Editor of "Medicamenteuze Therapie" (third edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 1993 Editor of "Medicamenteuze Therapie" (second edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands
- 1991 Editor of "Medicamenteuze Therapie" (first edition) of the Boerhaave Committee for Postgraduate Medical Education, Leiden, The Netherlands

Advisory boards and consultancy (last ten years)

2011	Eli Lilly, USA
2009 - 2010	MSD, USA
2008 - 2011	Roche, Scientific Advisory Board, USA
2006 - 2010	GlaxoSmithKline, The Netherlands
2005	Kudos, United Kingdom
2004	Boehringer, Germany
2004	Bristol-Myers Squibb
2003	Novartis, Switzerland
2003	Bayer, Germany
2003	Cyclacel, United Kingdom
2003 - 2010	AstraZeneca, United Kingdom
2003 - 2010	Eisai, United Kingdom
2003 - 2010	GlaxoSmithKline, USA

EXTERNAL FUNDING

Title	Funding source (fellow name)	Total value (€)	Time period
Grants			
Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)	Horizon 2020; FP7	5,996,929	2015-2019
Upfront DPYD pharmacogenotyping, -phenotyping and cost-analysis	Alpe d'Huzes-Dutch Cancer Society	1,100,000	2014-2017
Modulated Drug Absorption as a novel strategy to improve oral drug treatment in oncology	SenterNovem IK	1,900,000	2010-2013
Onconet	MSD	2,000,000	2009-2014
Crossing the barrier: from intravenous to effective oral formulations of chemotherapy.	ZonMw	480,000	2009-2011
Prediction of pharmacokinetic interactions between complementary, alternative medicines and (new) anticancer drugs.	Dutch Cancer Society	350,000	2007 - 2011
Pharmacogenetic guided and cost study of fluoropyrimidines in cancer patients.	NutsOhra	90,000	2007
Rapporteur grant	MEB-CBG	50,000	2006
Clinical proteomics in breast cancer.	Dutch Cancer Society	180,000	2005 - 2006
Compound Mrp2 (Abcc2) and other transporter knockout mice as tools to study determinants of pharmacokinetics and toxicity risks of anticancer drugs, and optimization of chemotherapy.	Dutch Cancer Society	300,000	2003 - 2007
The use of novel pharmacodynamic end-points in early clinical trials: focus on farnesyltransferase inhibitors.	Dutch Cancer Society	350,000	2003 - 2007
Aluminium 96 wells GeneAmp PCR System 9700 of Applied Biosystems	Nijbakker-Morra Foundation	8,500	2005

Pharmacogenotyping and phenotyping of patients with cancer: relationships with anticancer drug toxicity.	International Union Against Cancer (IUCC)	55,000	2003
Biotransformation of anti cancer drugs	Nijbakker-Morra Foundation	12,000	2001
Bayesian adaptive dosing in cyclophosphamide-thiotepa-carboplatin (CTC) and mitoxantrone-thiotepa (MT) high dose chemotherapy regimens	Dutch Cancer Society	300,000	2000
Modulation of cytochrome P450 (CYP) and P-glycoprotein (Pgp) and BCRP activity in guttwall and liver as major determinants of poor oral bioavailability of anticancer drugs: preclinical and clinical studies	Dutch Cancer Society	1,400,000	2000
Mechanism of reduced cellular accumulation of topoisomerase I inhibitors	Dutch Cancer Society	300,000	1998
Pharmacology of orally administered taxanes: a preclinical mechanistic study and clinical evaluation	Dutch Cancer Society	300,000	1997
Population analysis of anticancer drug treatment	European Community Biomed-2	840,000	1997
Mechanism of synergy of platinum compounds and topoisomerase I inhibitors <i>in vitro</i> and <i>in vivo</i> in patients with solid tumors	Dutch Cancer Society	300,000	1996
Influence of dexamethasone on the uptake of cytostatic drugs in a rat tumor model	Nijbakker-Morra Foundation	11,000	1995
Individualization of cisplatin chemotherapy in patients with solid tumors using a predetermined pharmacokinetic-dynamic-response relationship	Dutch Cancer Society	200,000	1994
Individualization of cisplatin therapy using a previously determined pharmacokinetic-dynamic-response relationship	Maurits and Anna de Kock Foundation	30,000	1994
Influence of dexamethasone on brain tumor uptake of cytostatic drugs in a rat model.	Dutch Cancer Society	40,000	1993
Clinical response in relationship to DNA-adduct formation: a pharmacokinetic-dynamic study	Nijbakker-Morra Foundation	12,000	1992
Fellowships			
M Joerger	UICC	40,000	2005
M Joerger	ESMO	40,000	2006

Signing this final page indicates approval of all pages.



Number of pages is 62

Professor Jan H.M. Schellens MD PhD, date: 12-10-2016